0001558370-21-015489.txt : 20211110 0001558370-21-015489.hdr.sgml : 20211110 20211110161057 ACCESSION NUMBER: 0001558370-21-015489 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211110 DATE AS OF CHANGE: 20211110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-PATH HOLDINGS INC CENTRAL INDEX KEY: 0001133818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870652870 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36333 FILM NUMBER: 211396672 BUSINESS ADDRESS: STREET 1: 4710 BELLAIRE BOULEVARD STREET 2: SUITE 210 CITY: BELLAIRE STATE: TX ZIP: 77401 BUSINESS PHONE: (832) 742-1357 MAIL ADDRESS: STREET 1: 4710 BELLAIRE BOULEVARD STREET 2: SUITE 210 CITY: BELLAIRE STATE: TX ZIP: 77401 FORMER COMPANY: FORMER CONFORMED NAME: OGDEN GOLF CO CORP DATE OF NAME CHANGE: 20010205 10-Q 1 bpth-20210930x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission file number: 001-36333

Bio-Path Holdings, Inc.

(Exact name of registrant as specified in its charter)


Delaware		87-0652870
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)


4710 Bellaire Boulevard, Suite 210, Bellaire, Texas		77401
(Address of principal executive offices)		(Zip Code)

(832) 742-1357

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.001 per share	BPTH	The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At November 5, 2021, the Company had 7,160,164 outstanding shares of common stock, par value $0.001 per share.

Table of Contents

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “our,” “us,” “the Company” and “Bio-Path” refer to Bio-Path Holdings, Inc. and its subsidiary. Bio-Path Holdings, Inc.’s wholly-owned subsidiary, Bio-Path, Inc., is sometimes referred to herein as “Bio-Path Subsidiary.”

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements can be identified by words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” “project,” “goal,” “strategy,” “future,” “likely,” “may,” “should,” “will” and variations of these words and similar references to future periods, although not all forward-looking statements contain these identifying words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances, including those discussed in “Item 1A. Risk Factors” to Part I of our Annual Report on Form 10-K as of the fiscal year ended December 31, 2020, and in other reports or documents we file with the U.S. Securities and Exchange Commission (“SEC”). As a result, our actual results and financial condition may differ materially from those expressed or forecasted in the forward-looking statements, and you should not rely on such forward-looking statements. We can give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them do, what impact they will have on our results of operations and financial condition. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

●the impact, risks and uncertainties related to COVID-19 and actions taken by governmental authorities or others in connection therewith;

●our lack of significant revenue to date, our history of recurring operating losses and our expectation of future operating losses;

●our need for substantial additional capital and our need to delay, reduce or eliminate our drug development and commercialization efforts if we are unable to raise additional capital;

●the highly-competitive nature of the pharmaceutical and biotechnology industry and our ability to compete effectively;

●the success of our plans to use collaboration arrangements to leverage our capabilities;

●our ability to retain and attract key personnel;

●the risk of misconduct of our employees, agents, consultants and commercial partners;

●disruptions to our operations due to expansions of our operations;

●the costs we would incur if we acquire or license technologies, resources or drug candidates;

●risks associated with product liability claims;

●our reliance on information technology systems and the liability or interruption associated with cyber-attacks or other breaches of our systems;

●our ability to use net operating loss carryforwards;

●provisions in our charter documents and state law that may prevent a change in control;

●work slowdown or stoppage at government agencies could negatively impact our business;

●our need to complete extensive clinical trials and the risk that we may not be able to demonstrate the safety and efficacy of our drug candidates;

●risks that our clinical trials may be delayed or terminated;

●our ability to obtain domestic and/or foreign regulatory approval for our drug candidates;

●changes in existing laws and regulations affecting the healthcare industry;

●our reliance on third parties to conduct clinical trials for our drug candidates;

●our ability to maintain orphan drug exclusivity for our drug candidates;

●our reliance on third parties for manufacturing our clinical drug supplies;

●risks associated with the manufacture of our drug candidates;

●our ability to establish sales and marketing capabilities relating to our drug candidates;

●market acceptance of our drug candidates;

●third-party payor reimbursement practices;

●our ability to adequately protect the intellectual property of our drug candidates;

Table of Contents

●infringement on the intellectual property rights of third parties;

●costs and time relating to litigation regarding intellectual property rights;

●our ability to adequately prevent disclosure by our employees or others of trade secrets and other proprietary information;

●our need to raise additional capital;

●the volatility of the trading price of our common stock;

●our common stock being thinly traded;

●our ability to issue shares of common or preferred stock without approval from our stockholders;

●our ability to pay cash dividends;

●costs and expenses associated with being a public company; and

●our ability to maintain compliance with the listing standards of the Nasdaq Capital Market.

Please also refer to “Item 1A. Risk Factors” to Part I of our Annual Report on Form 10-K as of the fiscal year ended December 31, 2020, “Item 1A. Risk Factors” to Part II of this Quarterly Report on Form 10-Q and other reports or documents we file with the SEC for a discussion of risks and factors that could cause our actual results and financial condition to differ materially from those expressed or forecasted in this Quarterly Report on Form 10-Q.

Any forward-looking statement made by us in this Quarterly Report on Form 10-Q is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. However, you should carefully review the risk factors set forth in other reports or documents we file from time to time with the SEC.

Table of Contents

TABLE OF CONTENTS


		Page
PART I - FINANCIAL INFORMATION		5
Item 1.	Financial Statements	5
	Condensed Consolidated Balance Sheets (Unaudited)	5
	Condensed Consolidated Statements of Operations (Unaudited)	6
	Condensed Consolidated Statements of Cash Flows (Unaudited)	7
	Condensed Consolidated Statements of Shareholders’ Equity (Unaudited)	8
	Notes to the Unaudited Condensed Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4.	Controls and Procedures	21
PART II - OTHER INFORMATION		22
Item 1.	Legal Proceedings	22
Item 1A.	Risk Factors	22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3.	Defaults Upon Senior Securities	22
Item 4.	Mine Safety Disclosures	22
Item 5.	Other Information	22
Item 6.	Exhibits	23
Signature		24

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BIO-PATH HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)

(Unaudited)


	As of September 30,		As of December 31,
	2021		2020

Assets

Current assets
Cash	$	26,601	$	13,755
Prepaid drug product		2,113		1,273
Other current assets		1,519		928
Total current assets		30,233		15,956

Fixed assets
Furniture, fixtures & equipment		1,076		1,029
Less accumulated depreciation		(854)		(798)
		222		231

Right of use operating assets		225		288

Total Assets	$	30,680	$	16,475

Liabilities & Shareholders' Equity

Current liabilities
Accounts payable	$	417	$	100
Accrued expenses		657		975
Current portion of lease liabilities		88		94
Total current liabilities		1,162		1,169

Noncurrent lease liabilities		172		236

Total Liabilities		1,334		1,405

Shareholders' equity
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding		—		—

Common stock, $.001 par value; 200,000 shares authorized; 7,160 and 4,542 shares issued and outstanding, respectively		7		5

Additional paid in capital		102,884		82,286
Accumulated deficit		(73,545)		(67,221)

Total shareholders' equity		29,346		15,070

Total Liabilities & Shareholders' Equity	$	30,680	$	16,475

SEE ACCOMPANYING NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Table of Contents

BIO-PATH HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020

Operating expenses

Research and development	$	981	$	2,000	$	3,002	$	5,038
General and administrative		1,088		970		3,324		3,319

Total operating expenses		2,069		2,970		6,326		8,357

Net operating loss	$	(2,069)	$	(2,970)	$	(6,326)	$	(8,357)

Other income
Interest income		—		2		2		25

Total other income		—		2		2		25

Net loss	$	(2,069)	$	(2,968)	$	(6,324)	$	(8,332)

Net loss per share, basic and diluted	$	(0.29)	$	(0.80)	$	(0.96)	$	(2.26)
Basic and diluted weighted average number of common shares outstanding		7,038		3,692		6,578		3,692

SEE ACCOMPANYING NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Table of Contents

BIO-PATH HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Nine Months Ended September 30,
	2021		2020

Cash flow from operating activities

Net loss	$	(6,324)	$	(8,332)

Adjustments to reconcile net loss to net cash used in operating activities

Stock-based compensation		591		432
Amortization of right of use assets		63		58
Depreciation		56		54
(Increase) decrease in operating assets
Prepaid drug product		(840)		(204)
Other current assets		(591)		(489)
Increase (decrease) in operating liabilities
Accounts payable and accrued expenses		(1)		176
Lease liabilities		(70)		(63)

Net cash used in operating activities		(7,116)		(8,368)

Cash flow from investing activities

Purchases of furniture, fixtures & equipment		(47)		—

Net cash used in investing activities		(47)		—

Cash flow from financing activities

Net proceeds from sale of common stock		15,852		—
Net proceeds from exercise of warrants		4,157		—

Net cash provided by financing activities		20,009		—

Net increase (decrease) in cash		12,846		(8,368)

Cash, beginning of period		13,755		20,426

Cash, end of period	$	26,601	$	12,058

SEE ACCOMPANYING NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Table of Contents

BIO-PATH HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands)

(Unaudited)


				Additional
	Common Stock			Paid in		Accumulated
Description	Shares	Amount		Capital		Deficit		Total

Balance at June 30, 2020	3,692	$	4	$	77,710	$	(61,703)	$	16,011

Stock-based compensation	—		—		143		—		143

Net loss	—		—		—		(2,968)		(2,968)

Balance at September 30, 2020	3,692	$	4	$	77,853	$	(64,671)	$	13,186

Balance at June 30, 2021	6,960	$	7	$	101,223	$	(71,476)	$	29,754

Issuance of common stock, net of fees	200		—		1,399		—		1,399

Stock-based compensation	—		—		262		—		262

Net loss	—		—		—		(2,069)		(2,069)

Balance at September 30, 2021	7,160	$	7	$	102,884	$	(73,545)	$	29,346


				Additional
	Common Stock			Paid in		Accumulated
Description	Shares	Amount		Capital		Deficit		Total

Balance at December 31, 2019	3,692	$	4	$	77,421	$	(56,339)	$	21,086

Stock-based compensation	—		—		432		—		432

Net loss	—		—		—		(8,332)		(8,332)

Balance at September 30, 2020	3,692	$	4	$	77,853	$	(64,671)	$	13,186

Balance at December 31, 2020	4,542	$	5	$	82,286	$	(67,221)	$	15,070

Issuance of common stock, net of fees	2,189		2		15,850		—		15,852

Exercise of warrants, net of fees	429		—		4,157		—		4,157

Stock-based compensation	—		—		591		—		591

Net loss	—		—		—		(6,324)		(6,324)

Balance at September 30, 2021	7,160	$	7	$	102,884	$	(73,545)	$	29,346

SEE ACCOMPANYING NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Table of Contents

BIO-PATH HOLDINGS, INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

Unless the context requires otherwise, references in these Notes to the Condensed Consolidated Financial Statements to “we,” “our,” “us,” “the Company” and “Bio-Path” refer to Bio-Path Holdings, Inc. and its subsidiary. Bio-Path Holdings, Inc.’s wholly-owned subsidiary, Bio-Path, Inc., is sometimes referred to herein as “Bio-Path Subsidiary.”

The accompanying unaudited condensed interim financial statements have been prepared in conformity with the authoritative U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of the Company as of and for the fiscal year ended December 31, 2020. The results of operations for the period ended September 30, 2021, are not necessarily indicative of the results for a full-year period.

1. Organization and Business

The Company is a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company’s drug delivery and antisense technology, called DNAbilize®, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The Company believes this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize® delivered antisense drug substances are systemically distributed throughout the body to allow for reduction or elimination of target proteins in blood diseases and solid tumors. Through testing in numerous animal studies and treatment in over 80 patients, the Company’s DNAbilize® drug candidates have demonstrated an excellent safety profile. DNAbilize® is a registered trademark of the Company. Using DNAbilize® as a platform for drug development and manufacturing, the Company currently has four antisense drug candidates in development to treat at least five different cancer disease indications.

The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates. As the Company has not begun its planned principal operations of commercializing a product candidate, the Company’s activities are subject to significant risks and uncertainties, including the potential requirement to secure additional funding, the outcome of the Company’s clinical trials and failing to operationalize the Company’s current drug candidates before another company develops similar products.

2. Significant Accounting Policies

Net Loss Per Share – Basic net loss per common share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Although there were warrants and stock options outstanding as of September 30, 2021 and 2020, no potential common shares are included in the computation of any diluted per share amount, as they would be antidilutive. Consequently, diluted net loss per share as presented in the condensed consolidated financial statements is equal to basic net loss per share for the three and nine months ended September 30, 2021 and 2020. The calculation of diluted earnings per share for 2021 did not include 485,908 shares and 429,791 shares issuable pursuant to the exercise of outstanding common stock options and warrants, respectively, as of September 30, 2021 as the effect would be antidilutive. The calculation of diluted earnings

Table of Contents

per share for 2020 did not include 274,008 shares and 858,698 shares issuable pursuant to the exercise of outstanding common stock options and warrants, respectively, as of September 30, 2020 as the effect would be antidilutive.

Fair Value - The fair values of cash and cash equivalents, accounts payable and accrued liabilities approximate their carrying values because of the short-term maturities of these instruments.

3. Prepaid Drug Product

Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future clinical development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. The Company recognized certain expenses and incurred installment costs for its contract drug manufacturing and raw material suppliers with prepayments totaling $1.3 million as of December 31, 2020 pursuant to drug supply contracts for the manufacture and delivery of prexigebersen for testing in a Phase 2 clinical trial and BP1002 for testing in a Phase 1 clinical trial. The Company recognized certain expenses and incurred additional installment costs during the first nine months of 2021, with advanced payments remaining to be expensed totaling $2.1 million as of September 30, 2021.

4. Other Current Assets

As of September 30, 2021, other current assets included prepaid expenses of $1.5 million, comprised primarily of prepayments of $1.0 million made for the Company’s clinical trials for BP1002 in lymphoma, prexigebersen in AML and prexigebersen-A in solid tumors as well as prepaid insurance of $0.4 million and prepaid expenses related to preclinical studies of $0.1 million. As of December 31, 2020, other current assets included prepaid expenses of $0.9 million, comprised primarily of prepayments of $0.6 million made for the Company’s clinical trials for BP1002 in lymphoma and prexigebersen-A in solid tumors as well as prepaid insurance of $0.3 million.

5. Accounts Payable

As of September 30, 2021, current liabilities included accounts payable of $0.4 million, comprised primarily of amounts owed for drug supply manufacturing of $0.3 million and legal and patent fees of $0.1 million. As of December 31, 2020, current liabilities included accounts payable of $0.1 million, comprised primarily of investor relations expenses and legal and patent fees of $0.1 million.

6. Accrued Expense

As of September 30, 2021, current liabilities included accrued expenses of $0.7 million, comprised primarily of accrued employee vacation and bonus expenses of $0.3 million, manufacturing and testing services of $0.1 million, professional and consulting fees of $0.1 million, preclinical study expenses of $0.1 million and other accrued expenses of $0.1 million. As of December 31, 2020, current liabilities included accrued expenses of $1.0 million, comprised primarily of expenses related to the Company’s clinical trial for prexigebersen in AML of $0.4 million, accrued employee vacation and bonus expenses of $0.4 million, manufacturing expenses of $0.1 million and other accrued expenses of $0.1 million.

7. Stockholders’ Equity

Issuances of Common Stock - On February 16, 2021, the Company entered into a placement agency agreement with Roth Capital Partners, LLC relating to a public offering of 1,710,600 shares of its common stock for gross proceeds of approximately $13.0 million under the Company’s shelf registration statement on Form S-3 (File No. 333-231537) (the “2019 Shelf Registration Statement”), which was declared effective by the SEC on June 5, 2019 (the “2021 Public Offering”). In addition, on February 16, 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to sell an aggregate of 1,650,000 shares of its common stock in the 2021 Public Offering to such investors. The 2021 Public Offering closed on February 18, 2021. The net proceeds from the offerings, after deducting the placement agent’s fees and expenses and the Company’s offering expenses, were approximately $12.2 million.

During the nine months ended September 30, 2021, the Company issued an aggregate of 428,907 shares of its common stock pursuant to the exercise of warrants at a weighted average exercise price of approximately $9.71 per share. The net proceeds to the Company from the exercise of the warrants were approximately $4.2 million.

Table of Contents

At-The-Market Offering Agreement - On July 13, 2020, the Company entered into an At-The-Market Offering Agreement (the “Offering Agreement”) with H. C. Wainwright & Co., LLC (“Wainwright”), as sales agent and/or principal, pursuant to which the Company may offer and sell, from time to time, through or to Wainwright, shares of the Company’s common stock. Sales of shares of common stock under the Offering Agreement were previously made pursuant to the 2019 Shelf Registration Statement and a related prospectus supplement filed with the SEC on July 14, 2020, for an aggregate offering price of up to $7.0 million. From and after August 18, 2021, sales of shares of common stock under the Offering Agreement will be made pursuant to the 2019 Shelf Registration Statement and a related prospectus supplement filed with the SEC on August 18, 2021, for an aggregate offering price of up to $10.0 million. Under the Offering Agreement, Wainwright may sell shares by any method deemed to be an “at the market” offering as defined in Rule 415 under the Securities Act of 1933, as amended. The Company will pay Wainwright a commission of 3% of the aggregate gross proceeds from each sale of shares under the Offering Agreement and has agreed to provide Wainwright with customary indemnification and contribution rights. The Company has also agreed to reimburse Wainwright for certain specified expenses.

During the nine months ended September 30, 2021, the Company offered and sold 478,800 shares of its common stock under the Offering Agreement for net proceeds of approximately $3.7 million.

Stockholders’ Equity totaled $29.3 million as of September 30, 2021 compared to $15.1 million as of December 31, 2020. There were 7,160,164 shares of common stock issued and outstanding as of September 30, 2021. There were no shares of preferred stock issued and outstanding as of September 30, 2021.

8. Stock-Based Compensation Plan

The 2017 Plan – On December 21, 2017, the Company’s stockholders approved the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (as amended, the “2017 Plan”), which replaced the First Amended 2007 Stock Incentive Plan, as amended (the “2007 Plan”). The 2007 Plan expired by its terms in January 2018, and no awards were made under the 2007 Plan from the approval of the 2017 Plan on December 21, 2017 until the expiration of the 2007 Plan. The 2017 Plan provides for the grant of Incentive Stock Options, Non-Qualified Stock Options, Restricted Shares, Restricted Share Units, Stock Appreciation Rights, Performance-Based Awards and other stock-based awards, or any combination of the foregoing to the Company’s employees, non-employee directors and consultants. On December 19, 2019, the Company’s stockholders approved an amendment to the 2017 Plan to increase the number of shares reserved for grant and issuance pursuant to the 2017 Plan by 600,000 shares to 660,000 shares. Under the 2017 Plan, the exercise price of awards is determined by the Board of Directors or the compensation committee of the Board of Directors, and for options intended to qualify as qualified Incentive Stock Options, may not be less than the fair market value as determined by the closing stock price at the date of the grant. Each option and award under the 2017 Plan shall vest and expire as determined by the Board of Directors or the compensation committee. Options expire no later than ten years from the date of grant. All grants provide for accelerated vesting if there is a change of control, as defined in the 2017 Plan.

Stock-based compensation expense for the three months ended September 30, 2021 and 2020 was $0.3 million and $0.1 million, respectively. Of these amounts, stock-based compensation expense for personnel involved in the Company’s general and administrative activities for the three months ended September 30, 2021 and 2020 was $0.2 million and $0.1 million, respectively. Stock-based compensation expense for personnel involved in the Company’s research and development activities for the three months ended September 30, 2021 and 2020 was $46,000 and $27,000, respectively.

Stock-based compensation expense for the nine months ended September 30, 2021 and 2020 was $0.6 million and $0.4 million, respectively. Of these amounts, stock-based compensation expense for personnel involved in the Company’s general and administrative activities for the nine months ended September 30, 2021 and 2020 was $0.5 million and $0.4 million, respectively. Stock-based compensation expense for personnel involved in the Company’s research and development activities for each of the nine months ended September 30, 2021 and 2020 was $0.1 million.

Table of Contents

The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock options granted, with the following weighted-average assumptions for options granted in the nine months ended September 30, 2021 and 2020, respectively:


	2021		2020
Risk-free interest rate	1.15	%	0.50	%
Expected volatility	128	%	122	%
Expected term in years	6.0		6.0
Dividend yield	—	%	—	%

The following summary represents option activity under the Company’s stock-based compensation plans for the nine months ended September 30, 2021:


		Weighted-
		Average
		Exercise
	Options	Price
	(in thousands)
Outstanding at December 31, 2020	274	$	20.57
Granted	212		7.02
Outstanding at September 30, 2021	486		14.58
Exercisable at September 30, 2021	156	$	30.83

As of September 30, 2021, the aggregate intrinsic value of outstanding stock options was $33,000. The aggregate intrinsic value represents the total pretax intrinsic value (the difference between the Company’s closing stock price on September 30, 2021 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on September 30, 2021. This amount changes based on the fair value of the Company’s stock.

As of September 30, 2021, unamortized stock-based compensation expense for all outstanding options was $1.6 million, which is expected to be recognized over a weighted average vesting period of 2.7 years.

9. Commitments and Contingencies

Drug Supplier Project Plan –Total commitments for the Company’s drug supplier project plan were $3.0 million as of September 30, 2021, comprised of $1.9 million for the manufacture of prexigebersen, BP1002, and BP1003 drug products, $0.9 million for manufacture of the Company’s Grb2 drug substance, $0.1 million for manufacturing development and $0.1 million for testing services. The Company expects to incur $2.2 million of these commitments over the next 12 months.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

When you read this Item of this Quarterly Report on Form 10-Q, it is important that you also read the unaudited financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and notes thereto included in our Annual Report on Form 10-K as of the fiscal year ended December 31, 2020. This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations, and intentions. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements due to the impact, risks and uncertainties related to COVID-19 and actions taken by governmental authorities or others in connection therewith. To date, COVID-19’s impact on our operations has been limited to the inability to travel to clinical trial sites, clinical trial sites not allowing nonessential personnel on site for the purpose of monitoring activity and delays in the manufacture of our drug requirements by contracted third-party manufacturers. We anticipate COVID-19 may have an effect on patient recruiting in the near term as social distancing mandates are in effect. We believe these operational issues can be managed through remote monitoring capabilities currently being developed and deployed. Our actual results could also differ materially from those anticipated in these forward-looking statements for many other reasons, including the matters discussed in “Item 1A. Risk Factors” to Part I of our Annual Report on Form 10-K as of the fiscal year ended December 31, 2020, the matters discussed in “Item 1A. Risk Factors” to Part II of this Quarterly Report on Form 10-Q, and other risks and uncertainties discussed in filings made with the SEC. See “Cautionary Note Regarding Forward-Looking Statements” in this Quarterly Report on Form 10-Q for additional discussion regarding risks associated with forward-looking statements.

Overview

We are a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize®, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. We believe this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize® delivered antisense drug substances are systemically distributed throughout the body to allow for reduction or elimination of target proteins in blood diseases and solid tumors. Through testing in numerous animal studies and treatment in over 80 patients, our DNAbilize® drug candidates have demonstrated an excellent safety profile. DNAbilize® is a registered trademark of the Company.

Using DNAbilize® as a platform for drug development and manufacturing, we currently have four drug candidates in development to treat at least five different cancer disease indications. Our lead drug candidate, prexigebersen (pronounced prex” i je ber’ sen), which targets growth factor receptor-bound protein 2 (Grb2), initially started the efficacy portion of a Phase 2 clinical trial for untreated acute myeloid leukemia (“AML”) patients in combination with low-dose cytarabine (“LDAC”). The interim data released on March 6, 2019 showed that 11 (65%) of the 17 evaluable patients had a response, including five (29%) who achieved complete remission (“CR”), including one CR with incomplete hematologic recovery (“CRi”) and one morphologic leukemia free state, and six (35%) stable disease responses, including two patients who had greater than a 50% reduction in bone marrow blasts. However, DNA hypomethylating agents are now the most frequently used agents in the treatment of elderly AML patients in the U.S. and Europe. As a result, Stage 2 of the Phase 2 trial in AML was amended to remove the combination treatment of prexigebersen and LDAC and replace it with the combination treatment of prexigebersen and decitabine, a DNA hypomethylating agent, for treatment of a second cohort of untreated AML patients. Since decitabine is also used as a treatment for relapsed/refractory AML patients, a cohort of relapsed/refractory AML patients was also added to the study.

The U.S. Food and Drug Administration (“FDA”) recently granted approval of venetoclax in combination with LDAC, decitabine or azacytidine (the latter two drugs are DNA hypomethylating agents) as frontline therapy for newly diagnosed AML in adults who are 75 years or older, or who have comorbidities precluding intensive induction chemotherapy. We believe this recent approval of the frontline venetoclax and decitabine combination therapy provides an opportunity for combining prexigebersen with the combination therapy for the treatment of de novo AML patients. Preclinical efficacy studies for the triple combination treatment of prexigebersen, decitabine and venetoclax in AML have been successfully completed. In the preclinical efficacy studies, four AML

Table of Contents

cancer cell lines were treated with three different combinations of decitabine, venetoclax and prexigebersen. Decrease in AML cell viability was the primary measure of efficacy. The triple combination of decitabine, venetoclax and prexigebersen showed significant improvement in efficacy in three of the four AML cell lines. Based on these results, we believe that adding prexigebersen to the treatment combination of decitabine and venetoclax could lead to improved efficacy in AML patients. Accordingly, we further amended Stage 2 of this Phase 2 clinical trial to add the triple combination treatment comprised of prexigebersen, decitabine and venetoclax.

Bio-Path’s approved amended Stage 2 for this Phase 2 clinical trial currently has three cohorts of patients. The first two cohorts will treat patients with the triple combination of prexigebersen, decitabine and venetoclax. The first cohort will include untreated AML patients, and the second cohort will include relapsed/refractory AML patients. Finally, the third cohort will treat relapsed/refractory AML patients, who are venetoclax-resistant or -intolerant, with the two-drug combination of prexigebersen and decitabine. The full trial design plans have approximately 98 evaluable patients for the first cohort having untreated AML patients with a preliminary review performed after 19 evaluable patients and a formal interim analysis after 38 evaluable patients. The full trial design plans have approximately 54 evaluable patients for each of the second cohort, having relapsed/refractory AML patients, and the third cohort, having AML patients who are venetoclax-resistant or -intolerant, in each case with a review performed after 19 evaluable patients. The study is anticipated to be conducted at ten clinical sites in the U.S., and Gail J. Roboz, MD is the national coordinating Principal Investigator for the Phase 2 trial. Dr. Roboz is a professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York City. On August 13, 2020, we announced the enrollment and dosing of the first patient in this approved amended Stage 2 of the Phase 2 clinical trial.

On April 5, 2021, we announced the successful completion of the safety run-in of Stage 2 of the Phase 2 clinical study. In the safety run-in of the triple combination, six evaluable patients were treated with the combination of prexigebersen, decitabine and venetoclax. These patients included four relapsed/refractory AML patients, and two newly diagnosed AML patients. In the preliminary safety data review, five of the patients (83%) responded to treatment, including four (67%) achieving CR and one (17%) achieving CRi. Recent publications provide that CR rates to combination treatment with decitabine and venetoclax (but without prexigebersen) are 42 to 52% for relapsed/refractory AML patients and 0 to 39% for relapsed/refractory secondary AML patients. Response rates to frontline treatment with decitabine and venetoclax (but without prexigebersen) are 62 to 71% for newly diagnosed AML patients. These preliminary data showed the treatment was well-tolerated and there were no dose limiting toxicities attributed to prexigebersen. Three patients remained on treatment for more than one cycle.

Our second drug candidate, Liposomal Bcl-2 (“BP1002”), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. On November 21, 2019, we announced that the FDA cleared an Investigational New Drug (“IND”) application for BP1002 for an initial Phase 1 clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients. The Phase 1 clinical trial is being conducted at several leading cancer centers, including The University of Texas MD Anderson Cancer Center, the Georgia Cancer Center and the Sarah Cannon Research Institute. Ian W. Flynn, MD is the national coordinating Principal Investigator for the Phase 1 trial. Dr. Flynn serves as the director of lymphoma research at the Sarah Cannon Research Institute. On November 19, 2020, we announced the enrollment and dosing of the first patient in the Phase 1 clinical trial.

Additionally, on August 24, 2021, we announced that the FDA cleared an IND application for BP1002 for an initial Phase 1/ 1b clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed AML patients. The Phase 1/1b clinical trial is anticipated to be conducted at several leading cancer centers in the United States, including the Weill Medical College of Cornell University, The University of Texas MD Anderson Cancer Center and the Georgia Cancer Center. Gail J. Roboz, M.D., will serve as Principal Investigator for the Phase 1/1b trial.

Our third drug candidate, Liposomal STAT3 (“BP1003”), targets the STAT3 protein and is currently in IND enabling studies as a potential treatment of pancreatic cancer, non-small cell lung cancer (“NSCLC”) and AML. Preclinical models have shown BP1003 to inhibit cell viability and STAT3 protein expression in NSCLC and AML cell lines. Further, BP1003 successfully penetrated pancreatic tumors and significantly enhanced the efficacy of gemcitabine, a treatment for patients with advanced pancreatic cancer, in a pancreatic cancer patient derived tumor model. Our lead indication for BP1003 is pancreatic cancer due to the severity of this disease and the lack of effective, life-extending treatments. For example, pancreatic adenocarcinoma is projected to be the second most lethal cancer behind lung cancer by 2030. Typical survival for a metastatic pancreatic cancer patient is about three to six months from diagnosis. We have successfully completed several IND enabling studies of BP1003 in 2021 and expect to complete one

Table of Contents

additional IND enabling study in 2022. If that additional study is successfully completed, our goal is to file an IND in 2022. Based on the filing of the IND, we expect to initiate the first-in-humans Phase 1 study of BP1003 in patients with refractory, metastatic solid tumors, including pancreatic cancer and NSCLC.

In addition, a modified product named prexigebersen-A, Bio-Path's fourth drug candidate, has shown to enhance chemotherapy efficacy in preclinical solid tumor models. Prexigebersen-A incorporates the same drug substance as prexigebersen but has a slightly modified formulation designed to enhance nanoparticle properties. In late 2019, we filed an IND application to initiate a Phase 1/1b clinical trial of prexigebersen-A in patients with solid tumors, including ovarian, endometrial, pancreatic and breast cancer. Ovarian cancer is one of the most common types of gynecologic malignancies, with approximately 50% of all cases occurring in women older than 63 years. On October 27, 2021, we announced that the FDA cleared the IND application for prexigebersen-A for the initial Phase 1/1b clinical trial, which allows the Company to proceed with next steps to open the clinical trial.

Our DNAbilize® technology-based products are available for out-licensing or partnering. We intend to apply our drug delivery technology template to new disease-causing protein targets to develop new nanoparticle antisense RNAi drug candidates. We have a new product identification template in place to define a process of scientific, preclinical, commercial and intellectual property evaluation of potential new drug candidates for inclusion into our drug product development pipeline. As we expand, we will look at indications where a systemic delivery is needed and antisense RNAi nanoparticles can be used to slow, reverse or cure a disease, either alone or in combination with another drug.

Our patent portfolio currently includes five issued patents in the U.S.:

Claims Related to DNAbilize®


Patent No.	Title	Date Issued
9,744,187	P-ethoxy nucleic acids for liposomal formulation	August 29, 2017

10,335,428	P-ethoxy nucleic acids for liposomal formulation	July 2, 2019

10,898,506	P-ethoxy nucleic acids for liposomal formulation	January 26, 2021

Compositions and Methods of Use for Specific Drug Targets


Patent No.	Title	Date Issued
10,927,379	Combination therapy with liposomal antisense oligonucleotides	February 23, 2021

11,041,153	P-ethoxy nucleic acids for STAT3 inhibition	June 22, 2021

We have six additional pending patent applications in the U.S. We continue our efforts to build protection around our technology as it safeguards our platform technology and target-specific technology, is a deterrent to would-be competitors and creates value around our core competencies.

We have certain intellectual property as the basis for our current drug products in clinical development, prexigebersen, prexigebersen-A, BP1002 and BP1003. We are developing RNAi antisense nanoparticle drug candidates based on our own patented technology to treat cancer and autoimmune disorders where targeting a single protein may be advantageous and result in reduced patient adverse effects as compared to small molecule inhibitors with off-target and non-specific effects. We have composition of matter and method of use intellectual property for the design and manufacture of antisense RNAi nanoparticle drug products.

As of September 30, 2021, we had an accumulated deficit of $73.5 million. Our net loss was $2.1 million and $3.0 million for the three months ended September 30, 2021 and 2020, respectively. Our net loss was $6.3 million and $8.3 million for the nine months ended September 30, 2021 and 2020, respectively. We expect to continue to incur significant operating losses, and we anticipate that our losses may increase substantially as we expand our drug development programs and commercialization efforts. To achieve profitability, we must enter into license or development agreements with third parties, or successfully develop and obtain

Table of Contents

regulatory approval for one or more of our drug candidates and effectively commercialize any drug candidates we develop. In addition, if we obtain regulatory approval of one or more of our drug candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Even if we succeed in developing and commercializing one or more of our drug candidates, we may not be able to generate sufficient revenue and we may never be able to achieve or sustain profitability. We expect to finance our foreseeable cash requirements through cash on hand, cash from operations, debt financings and public or private equity offerings. We may seek to access the public or private equity markets whenever conditions are favorable; however, there can be no assurance that we will be able to raise additional capital when needed or on terms that are favorable to us, if at all. Additionally, we may seek collaborations and license arrangements for our drug candidates. We currently have no lines of credit or other arranged access to debt financing.

Company History and Available Information

The Company was incorporated in May 2000 as a Utah corporation. In February 2008, Bio-Path Subsidiary completed a reverse merger with the Company, which at the time was traded over the counter and had no current operations. The prior name of the Company was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path Subsidiary became the directors and officers of Bio-Path Holdings, Inc. On March 10, 2014, our common stock ceased trading on the OTCQX and commenced trading on the Nasdaq Capital Market under the ticker symbol “BPTH.” Effective December 31, 2014, we changed our state of incorporation from Utah to Delaware through a statutory conversion pursuant to the Utah Revised Business Corporation Act and the Delaware General Corporation Law. Our principal executive offices are located at 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401, and our telephone number is (832) 742-1357.

Recent Accounting Pronouncements

There are no recent accounting pronouncements that have a material impact on our condensed consolidated financial statements.

Financial Operations Overview

Revenue

We have not generated significant revenues to date. Our ability to generate revenues from our drug candidates, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our drug candidates.

In the future, we may generate revenue from a combination of product sales, third-party grants, service agreements, strategic alliances and licensing arrangements. We expect that any revenue we generate will fluctuate due to the timing and amount of services performed, milestones achieved, license fees earned and payments received upon the eventual sales of our drug candidates, in the event any are successfully commercialized. If we fail to complete the development of any of our drug candidates or obtain regulatory approval for them, our ability to generate future revenue will be adversely affected.

Research and development expenses

Research and development expenses consist of costs associated with our research activities, including the development of our drug candidates. Our research and development expenses consist of:

●

expenses related to research and development personnel, including salaries and benefits, travel and stock-based compensation;

●

external research and development expenses incurred under arrangements with third parties, such as contract research organizations, clinical investigative sites, laboratories, manufacturing organizations and consultants; and

●

costs of materials used during research and development activities.

Table of Contents

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. If the goods will not be delivered, or services will not be rendered, then the capitalized advance payment is charged to expense.

We expect research and development expenses associated with the completion of the associated clinical trials to be substantial and to increase over time. The successful development of our drug candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete development of our drug candidates or the period, if any, in which material net cash inflows from our drug candidates may commence. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:

●

the rate of progress, results and costs of completion of ongoing clinical trials of our drug candidates;

●

the size, scope, rate of progress, results and costs of completion of any potential future clinical trials and preclinical tests of our drug candidates that we may initiate;

●

competing technological and market developments;

●

the performance of third-party manufacturers and suppliers;

●

the ability of our drug candidates, if they receive regulatory approval, to achieve market success;

●

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our drug candidates; and

●

the impact, risks and uncertainties related to COVID-19 and actions taken by governmental authorities or others in connection therewith.

A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate. For example, if the FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of a drug candidate or if we experience significant delays in enrollment in any clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

General and administrative expenses

Our general and administrative expenses consist primarily of salaries and benefits for management and administrative personnel, professional fees for legal, accounting and other services, travel costs and facility-related costs such as rent, utilities and other general office expenses.

Results of Operations

Comparisons of the Three Months Ended September 30, 2021 to the Three Months Ended September 30, 2020

Revenue. We had no revenue for each of the three months ended September 30, 2021 and 2020.

Research and Development Expense. Our research and development expense for the three months ended September 30, 2021 was $1.0 million, a decrease of $1.0 million compared to the three months ended September 30, 2020. The decrease in research and development expense was primarily due to timing of activities related to our clinical trial for prexigebersen in AML and timing of

Table of Contents

drug material manufacturing and shipping activities. The following table sets forth our research and development expenses (in thousands):


	Three Months Ended
	September 30,
	2021		2020
Research and development expense	$	935	$	1,973
Non-cash stock-based compensation expense		46		27
Total research and development expense	$	981	$	2,000

General and Administrative Expense. Our general and administrative expense for the three months ended September 30, 2021 was $1.1 million, an increase of $0.1 million compared to the three months ended September 30, 2020. The increase in general and administrative expense was primarily due to increased stock-based compensation expense. The following table sets forth our general and administrative expenses (in thousands):


	Three Months Ended
	September 30,
	2021		2020
General and administrative expense	$	872	$	854
Non-cash stock-based compensation expense		216		116
Total general and administrative expense	$	1,088	$	970

Net Operating Loss. Our net loss from operations for the three months ended September 30, 2021 was $2.1 million, a decrease of $0.9 million compared to the three months ended September 30, 2020.

Net Loss. Our net loss for the three months ended September 30, 2021 was $2.1 million, a decrease of $0.9 million compared to the three months ended September 30, 2020.

Net Loss per Share. Net loss per share, both basic and diluted, for the three months ended September 30, 2021 was $0.29, compared to $0.80 for the three months ended September 30, 2020. Net loss per share is calculated using the weighted average number of shares of common stock outstanding during the applicable periods and excludes stock options and warrants because they are antidilutive.

Comparisons of the Nine Months Ended September 30, 2021 to the Nine Months Ended September 30, 2020

Revenue. We had no revenue for each of the nine months ended September 30, 2021 and 2020.

Research and Development Expense. Our research and development expense for the nine months ended September 30, 2021 was $3.0 million, a decrease of $2.0 million compared to the nine months ended September 30, 2020. The decrease in research and development expense was primarily due to timing of activities related to our clinical trials for prexigebersen in AML and BP1002 in lymphoma, decreased drug material manufacturing expense and decreased preclinical study expenses. The following table sets forth our research and development expenses (in thousands):


	Nine Months Ended
	September 30,
	2021		2020
Research and development expense	$	2,882	$	4,966
Non-cash stock-based compensation expense		120		72
Total research and development expense	$	3,002	$	5,038

Table of Contents

General and Administrative Expense. Our general and administrative expense for each of the nine months ended September 30, 2021 and 2020 was $3.3 million. The following table sets forth our general and administrative expenses (in thousands):


	Nine Months Ended
	September 30,
	2021		2020
General and administrative expense	$	2,853	$	2,959
Non-cash stock-based compensation expense		471		360
Total general and administrative expense	$	3,324	$	3,319

Net Operating Loss. Our net loss from operations for the nine months ended September 30, 2021 was $6.3 million, a decrease of $2.0 million compared to the nine months ended September 30, 2020.

Net Loss. Our net loss for the nine months ended September 30, 2021 was $6.3 million, a decrease of $2.0 million compared to the nine months ended September 30, 2020.

Net Loss per Share. Net loss per share, both basic and diluted, for the nine months ended September 30, 2021 was $0.96, compared to $2.26 for the nine months ended September 30, 2020. Net loss per share is calculated using the weighted average number of shares of common stock outstanding during the applicable periods and excludes stock options and warrants because they are antidilutive.

Liquidity and Capital Resources

Overview

We have not generated significant revenues to date. Since our inception, we have funded our operations primarily through public and private offerings of our capital stock and other securities. We expect to finance our foreseeable cash requirements through cash on hand, cash from operations, debt financings and public or private equity offerings. We may seek to access the public or private equity markets whenever conditions are favorable; however, there can be no assurance that we will be able to raise additional capital when needed or on terms that are favorable to us, if at all. Additionally, we may seek collaborations and license arrangements for our drug candidates. We currently have no lines of credit or other arranged access to debt financing.

We had a cash balance of $26.6 million as of September 30, 2021, an increase of $12.8 million compared to December 31, 2020. We believe that our available cash at September 30, 2021 will be sufficient to meet obligations and fund our liquidity and capital expenditure requirements for at least the next 12 months.

Cash Flows

Operating Activities. Net cash used in operating activities for the nine months ended September 30, 2021 was $7.1 million. Excluding non-cash stock-based compensation expense of $0.6 million and depreciation and amortization expenses of $0.1 million included in net loss, net cash used in operating activities for the nine months ended September 30, 2021 consisted primarily of the net loss for the period of $6.3 million, an increase in current assets of $1.4 million and a decrease in operating liabilities of $0.1 million. Net cash used in operating activities for the nine months ended September 30, 2020 was $8.4 million. Excluding non-cash stock-based compensation expense of $0.4 million and depreciation and amortization expenses of $0.1 million included in net loss, net cash used in operating activities for the nine months ended September 30, 2020 consisted primarily of the net loss for the period of $8.3 million and an increase in current assets of $0.7 million, partially offset by an increase in operating liabilities of $0.1 million.

Investing Activities. Net cash used in investing activities for the nine months ended September 30, 2021 consisted of capital expenditures totaling $47,000 which were related to research and development equipment purchases. There were no investing activities for the nine months ended September 30, 2020.

Financing Activities. Net cash provided by financing activities for the nine months ended September 30, 2021 was $20.0 million. Net cash provided by financing activities consisted primarily of net proceeds of $12.2 million from the 2021 Public Offering

Table of Contents

and net proceeds of $3.7 million from sales of our common stock under the Offering Agreement, each as described below, as well as net proceeds of $4.2 million from the exercise of warrants to purchase shares of our common stock. There were no financing activities for the nine months ended September 30, 2020.

2019 Shelf Registration Statement

On May 16, 2019, we filed a shelf registration statement on Form S-3 with the SEC, which was declared effective by the SEC on June 5, 2019 (File No. 333-231537) (the “2019 Shelf Registration Statement”), at which time the offering of unsold securities under a previous shelf registration statement on Form S-3 filed with the SEC, which was declared effective by the SEC on January 9, 2017 (File No. 333-215205), was deemed terminated pursuant to Rule 415(a)(6) under the Securities Act. The 2019 Shelf Registration Statement was filed to register the offering, issuance and sale of (i) up to $125.0 million of our common stock, preferred stock, warrants to purchase common stock or preferred stock or any combination thereof, either individually or in units, and (ii) up to 5,149 shares of our common stock pursuant to the exercise of warrants that were issued in connection with a registered direct offering in 2016. The foregoing does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

At-The-Market Offering Agreement

On July 13, 2020, we entered into an At-The-Market Offering Agreement (the “Offering Agreement”) with H. C. Wainwright & Co., LLC (“Wainwright”), as sales agent and/or principal, pursuant to which we may offer and sell, from time to time, through or to Wainwright, shares of our common stock. Sales of shares of common stock under the Offering Agreement were previously made pursuant to the 2019 Shelf Registration Statement and a related prospectus supplement filed with the SEC on July 14, 2020, for an aggregate offering price of up to $7.0 million. From and after August 18, 2021, sales of shares of common stock under the Offering Agreement will be made pursuant to the 2019 Shelf Registration Statement and a related prospectus supplement filed with the SEC on August 18, 2021, for an aggregate offering price of up to $10.0 million. Under the Offering Agreement, Wainwright may sell shares by any method deemed to be an “at the market” offering as defined in Rule 415 under the Securities Act. We will pay Wainwright a commission of 3% of the aggregate gross proceeds from each sale of shares under the Offering Agreement and have agreed to provide Wainwright with customary indemnification and contribution rights. We have also agreed to reimburse Wainwright for certain specified expenses. During the three months ended September 30, 2021, we offered and sold 200,000 shares of our common stock under the Offering Agreement for net proceeds of approximately $1.4 million. As of September 30, 2021, we had offered and sold 1,328,000 shares of our common stock under the Offering Agreement for gross proceeds of approximately $8.4 million. The net proceeds from the offering, after deducting commissions and our offering expenses, were approximately $8.0 million.

2021 Public Offering

On February 16, 2021, we entered into a placement agency agreement with Roth Capital Partners, LLC relating to a public offering of 1,710,600 shares of our common stock for gross proceeds of approximately $13.0 million under the 2019 Shelf Registration Statement (the “2021 Public Offering”). In addition, on February 16, 2021, we entered into a securities purchase agreement with certain institutional investors pursuant to which we agreed to sell an aggregate of 1,650,000 shares of our common stock in the 2021 Public Offering to such investors. The 2021 Public Offering closed on February 18, 2021. The net proceeds from the 2021 Public Offering, after deducting the placement agent’s fees and expenses and our offering expenses, were approximately $12.2 million.

Future Capital Requirements

We expect to continue to incur significant operating expenses in connection with our ongoing activities, including conducting clinical trials, manufacturing and seeking regulatory approval of our drug candidates, prexigebersen, prexigebersen-A, BP1002 and BP1003. Accordingly, we will continue to require substantial additional capital to fund our projected operating requirements. Such additional capital may not be available when needed or on terms favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current and future operating plan. There can be no assurance that we will be able to continue to raise additional capital through the sale of our securities in the future. Our future capital requirements may change and will depend on numerous factors, which are discussed in detail in “Item

Table of Contents

1A. Risk Factors” to Part I of our Annual Report on Form 10-K as of the fiscal year ended December 31, 2020. For more information, see Note 1 to the Unaudited Condensed Consolidated Financial Statements included herein.

Off-Balance Sheet Arrangements

As of September 30, 2021, we did not have any material off-balance sheet arrangements.

Critical Accounting Policies

The preparation of financial statements in conformity with generally accepted accounting principles in the United States has required the management of the Company to make assumptions, estimates and judgments that affect the amounts reported in the financial statements, including the notes thereto, and related disclosures of commitments and contingencies, if any. We consider our critical accounting policies to be those that require the more significant judgments and estimates in the preparation of financial statements. There have been no significant changes to our critical accounting policies from those disclosed in Note 2 to our Consolidated Financial Statements included in our Annual Report on Form 10-K as of the year ended December 31, 2020.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

It is management’s responsibility to establish and maintain adequate disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures are controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including the company’s principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.

Our management, including our Chief Executive Officer (who is also our Chief Financial Officer), has reviewed and evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Following this review and evaluation, our management determined that as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

There were no material changes from the risk factors previously disclosed under “Item 1A. Risk Factors” to Part I of our Annual Report on Form 10-K as of the fiscal year ended December 31, 2020.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None.

Table of Contents

ITEM 6. EXHIBITS


Exhibit No.		Description of Exhibit
2.1		Agreement and Plan of Merger and Reorganization dated September 27, 2007, by and among the Company, Biopath Acquisition Corp., a Utah corporation and wholly owned subsidiary of the registrant, and Bio-Path, Inc., a Utah corporation (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on September 27, 2007).
3.1		Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed on January 6, 2015).
3.2		Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on February 9, 2018).
3.3		First Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 7, 2017).
3.4		Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on January 16, 2019).
31*		Certification of Principal Executive Officer and Principal Financial Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 Sarbanes Oxley Act of 2002.
32**		Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101*		The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets (Unaudited); (ii) Condensed Consolidated Statements of Operations (Unaudited); (iii) Condensed Consolidated Statements of Cash Flows (Unaudited); (iv) Condensed Consolidated Statements of Shareholders’ Equity (Unaudited); and (v) Notes to the Unaudited Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
104*		The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, formatted in Inline XBRL (included as Exhibit 101).

*Filed herewith.

**Furnished herewith.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Dated:	November 10, 2021	BIO-PATH HOLDINGS, INC.

		By:	/s/ Peter H. Nielsen
			Peter H. Nielsen
			President
			Chief Executive Officer
			(Principal Executive Officer)
			Chief Financial Officer
			(Principal Financial Officer)

EX-31.1 2 bpth-20210930xex31d1.htm EX-31.1

Exhibit 31

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL OFFICER

I, Peter H. Nielsen, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Bio-Path Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated: November 10, 2021	By:	/s/ Peter H. Nielsen
		Peter H. Nielsen
		Chief Executive Officer
		(Principal Executive Officer)
		Chief Financial Officer
		(Principal Financial Officer)

EX-32 3 bpth-20210930xex32.htm EX-32

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Bio-Path Holdings, Inc. (the “Company”) for the quarter ended September 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Peter H. Nielsen, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: November 10, 2021	By:	/s/ Peter H. Nielsen
		Peter H. Nielsen
		Chief Executive Officer
		Chief Financial Officer

EX-101.SCH 4 bpth-20210930.xsd EX-101.SCH 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Stock-Based Compensation Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accounts Payable (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Stock-Based Compensation Plan - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Prepaid Drug Product link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accounts Payable link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accrued Expense link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stock-Based Compensation Plan link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Prepaid Drug Product (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accrued Expense (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stock-Based Compensation Plan - Weighted-Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Stock-Based Compensation Plan - Option Activity Under Plan (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 bpth-20210930_cal.xml EX-101.CAL EX-101.DEF 6 bpth-20210930_def.xml EX-101.DEF EX-101.LAB 7 bpth-20210930_lab.xml EX-101.LAB Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Document Fiscal Year Focus Document Fiscal Period Focus Current Fiscal Year End Date Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash Cash Prepaid Expense, Current Prepaid drug product Other Assets, Current Other current assets Assets, Current Total current assets Assets, Noncurrent [Abstract] Fixed assets Property, Plant and Equipment, Gross Furniture, fixtures & equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Property, Plant and Equipment, Net Furniture, fixtures & equipment, net Operating Lease, Right-of-Use Asset Right of use operating assets Assets Total Assets Liabilities and Equity [Abstract] Liabilities & Shareholders' Equity Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Accounts payable, current Accrued Liabilities, Current Accrued expense Accrued expenses Operating Lease, Liability, Current Current portion of lease liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Noncurrent lease liabilities Liabilities Total Liabilities Stockholders' Equity Attributable to Parent [Abstract] Shareholders' equity Preferred Stock, Value, Issued Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding Common Stock, Value, Issued Common stock, $.001 par value; 200,000 shares authorized; 7,160 and 4,542 shares issued and outstanding, respectively Additional Paid In Capital Additional paid in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Ending Balance Beginning Balance Total shareholders' equity Stockholders' Equity total amount Liabilities and Equity Total Liabilities & Shareholders' Equity Preferred Stock, Par or Stated Value Per Share Preferred Stock, par value Preferred Stock, Shares Authorized Preferred Stock, shares authorized Preferred Stock, Shares Issued Preferred Stock, shares issued Preferred Stock, Shares Outstanding Preferred Stock, shares outstanding Common Stock, Par or Stated Value Per Share Common Stock, par value Common Stock, Shares Authorized Common Stock, shares authorized Common Stock, Shares, Issued Common Stock, shares issued Common Stock, Shares, Outstanding Common Stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Operating Expenses [Abstract] Operating expenses Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Net operating loss Nonoperating Income (Expense) [Abstract] Other income Investment Income, Interest Interest income Nonoperating Income (Expense) Total other income Net Income (Loss) Attributable to Parent Net loss Net loss Earnings Per Share, Basic and Diluted Net loss per share, basic and diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted weighted average number of common shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flow from operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Share-based Compensation Stock-based compensation Amount of operating lease right-of-use assets amortization. Operating Lease Right of Use Assets Amortization Amortization of right of use assets Depreciation Depreciation Increase (Decrease) in Operating Assets [Abstract] (Increase) decrease in operating assets Increase (Decrease) in Prepaid Expense Prepaid drug product Increase (Decrease) in Other Current Assets Other current assets Increase (Decrease) in Operating Liabilities [Abstract] Increase (decrease) in operating liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Amount of increase (decrease) in operating lease liabilities. Increase Decrease In Operating Lease Liabilities Lease liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flow from investing activities Payments to Acquire Property, Plant, and Equipment Purchases of furniture, fixtures & equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flow from financing activities Proceeds from Issuance of Common Stock Net proceeds from sale of common stock Proceeds from Stock Options Exercised Net proceeds from exercise of warrants Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Period Increase (Decrease) Net increase (decrease) in cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, end of period Cash, beginning of period CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statement [Table] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid in Capital. Retained Earnings [Member] Accumulated Deficit Statement [Line Items] Shares, Outstanding Ending Balance (in shares) Beginning Balance (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock, net of fees Stock Issued During Period, Shares, New Issues Shares issued (in shares) Issuance of common stock, net of fees (in shares) Equity impact of the value of warrants exercised during the period. Stock Issue During Period Value Warrants Exercised Exercise of warrants, net of fees Number of new stock issued during the period warrants exercised. Stock Issue During Period Shares Warrants Exercised Exercise of warrants, net of fees (in shares) Adjustments to Additional Paid in Capital, Other Stock-based compensation Organization and Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization and Business Significant Accounting Policies Significant Accounting Policies [Text Block] Significant Accounting Policies Prepaid Drug Product Research And Development Disclosure [Text Block] Research and Development Disclosure [Text Block] Prepaid Drug Product Other Current Assets Other Current Assets [Text Block] Other Current Assets Accounts Payable The entire disclosure for accounts payable at the end of the reporting period. Accounts Payable Disclosure [Text Block] Accounts Payable Accrued Expense Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expense Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Stock-Based Compensation Plan Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Plan Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Fair Value Measurement, Policy [Policy Text Block] Fair Value Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of share-based payment award, stock options, valuation assumptions Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of option activity under stock-based compensation plans N/A Significant Accounting Policies [Table] Significant Accounting Policies [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share, amount Other Prepaid Expense, Current Prepaid drug product for testing Amount of advanced payments remaining to be expensed. Expected Advanced Payment to be Expensed Advanced payments remaining to be expensed Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Prepaid Expenses [Member]. Prepaid Expenses [Member] Prepaid Expenses [Member] Other Prepaid Expenses [Member]. Other Prepaid Expenses [Member] Other Prepaid Expenses [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research And Development Arrangement Contract To Perform For Others Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Represents the information pertaining to BP1002 in lymphoma and prexigebersen-A. Acutemyeloidleukemia Bp1002 In Lymphoma And Prexigebersen [Member] BP1002 in lymphoma, prexigebersen in AML and prexigebersen-A [Member] Prepaid Insurance Prepaid insurance Amount of prepaid expenses related to preclinical studies Prepaid Expenses Related to Preclinical Studies Prepaid expenses related to preclinical studies Accounts Payable [Table] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Manufacturing Costs [Member]. Manufacturing Costs [Member] Manufacturing Costs [Member] Accounts Payable [Line Items] Accounts Payable [Line Items] Carrying value as of the balance sheet date of obligations incurred through that date and payable for the Company's clinical trial (due within one year or within the normal operating cycle if longer). Accrued Clinical Trial Expenses, Current Accrued clinical trial expenses Carrying value as of the balance sheet date of obligations incurred and payable for employee vacation and bonus expenses . Accrued Vacation And Bonus Accrued vacation and bonus expenses Carrying value as of the balance sheet date of the obligations incurred through that date and payable for manufacturing and testing services. Accrued Manufacturing And Testing Expenses Manufacturing and testing services Amount of accrued manufacturing expense. Accrued Manufacturing Expense Manufacturing expenses Accrued Professional Fees, Current Professional and consulting fees Carrying value as of the balance sheet date of obligations incurred and payable for clinical and preclinical expenses. Accrued Clinical And Preclinical Expenses Accrued clinical and preclinical expenses Other Accrued Liabilities Other accrued expenses Disclosure - Stockholders' Equity - Additional Information [Abstract] Stockholders' Equity. Shareholders Equity [Table] Shareholders Equity [Table] Shareholders Equity [Line Items] Shareholders Equity [Line Items] Shareholders Equity [Line Items] Shares of stock issued as a result of the exercise of warrants. Stock Issued During Period Shares Warrants Exercised Stock issued during period shares warrants exercised Proceeds from Warrant Exercises Proceeds from warrant exercises Represents the maximum gross sales proceeds. Shares Proceeds Authorized Maximum aggregate offering price Represents the commission on aggregate gross proceeds. Commission Percentage On Aggregate Gross Proceeds Commission on aggregate gross proceeds (as a percent) The cash inflow from the additional capital contribution to the entity, after deducting commission and offering expenses. Net Proceeds From Issuance Of Common Stock Net proceeds Represents information pertaining to weighted average exercise price of common stock issued pursuant to exercise of warrants. Weighted Average Exercise Price Weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price, Outstanding Weighted-Average Exercise Price, Outstanding Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-Average Exercise Price, Exercisable Stock Based Compensation Plans [Table] Research And Development Expense [Member] Research and Development Expense [Member] General And Administrative Expense [Member] General and Administrative Expense [Member] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Information pertaining to the 2017 Stock Incentive Plan. Stock Incentive Plan2017 [Member] Stock Incentive Plan 2017 [Member] Stock Based Compensation Plans [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increase in number of shares reserved for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of shares reserved for grant and issuance Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Expiration period (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unamortized stock-based compensation expense for outstanding options Allocated Share-based Compensation Expense Stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Aggregate intrinsic value of outstanding stock options EX-101.PRE 8 bpth-20210930_pre.xml EX-101.PRE XML 9 bpth-20210930x10q_htm.xml IDEA: XBRL DOCUMENT 0001133818 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001133818 bpth:TwoThousandTwentyOnePublicOfferingMember 2021-02-16 2021-02-16 0001133818 us-gaap:RetainedEarningsMember 2021-09-30 0001133818 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001133818 bpth:AtMarketOfferingAgreementMember 2021-09-30 0001133818 us-gaap:RetainedEarningsMember 2021-06-30 0001133818 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001133818 2021-06-30 0001133818 us-gaap:RetainedEarningsMember 2020-12-31 0001133818 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001133818 bpth:AtMarketOfferingAgreementMember 2020-12-31 0001133818 us-gaap:RetainedEarningsMember 2020-09-30 0001133818 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001133818 us-gaap:RetainedEarningsMember 2020-06-30 0001133818 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001133818 2020-06-30 0001133818 us-gaap:RetainedEarningsMember 2019-12-31 0001133818 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001133818 us-gaap:CommonStockMember 2021-09-30 0001133818 us-gaap:CommonStockMember 2021-06-30 0001133818 us-gaap:CommonStockMember 2020-12-31 0001133818 us-gaap:CommonStockMember 2020-09-30 0001133818 us-gaap:CommonStockMember 2020-06-30 0001133818 us-gaap:CommonStockMember 2019-12-31 0001133818 bpth:StockIncentivePlan2017Member 2019-12-19 0001133818 bpth:StockIncentivePlan2017Member 2019-12-19 2019-12-19 0001133818 bpth:StockIncentivePlan2017Member 2021-01-01 2021-09-30 0001133818 2021-02-18 2021-02-18 0001133818 us-gaap:IPOMember 2021-02-16 2021-02-16 0001133818 bpth:OtherPrepaidExpensesMember bpth:AcutemyeloidleukemiaBp1002InLymphomaAndPrexigebersenMember 2020-12-31 0001133818 us-gaap:PreferredStockMember bpth:AtMarketOfferingAgreementMember 2021-09-30 0001133818 bpth:TestingServicesMember 2021-09-30 0001133818 bpth:ManufacturingDevelopmentMember 2021-09-30 0001133818 bpth:ManufacturerOfPrexigebersenAndBp1002DrugProductsMember 2021-09-30 0001133818 bpth:ManufactureOfDrugSubstanceMember 2021-09-30 0001133818 bpth:DrugSupplierProjectPlanMember 2021-09-30 0001133818 bpth:PrepaidExpensesMember bpth:AcutemyeloidleukemiaBp1002InLymphomaAndPrexigebersenMember 2021-09-30 0001133818 bpth:PrepaidExpensesMember 2021-09-30 0001133818 bpth:PrepaidExpensesMember bpth:AcutemyeloidleukemiaBp1002InLymphomaAndPrexigebersenMember 2020-12-31 0001133818 bpth:PrepaidExpensesMember 2020-12-31 0001133818 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001133818 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001133818 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001133818 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001133818 us-gaap:CommonStockMember bpth:AtMarketOfferingAgreementMember 2021-09-30 0001133818 2020-09-30 0001133818 2019-12-31 0001133818 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001133818 bpth:CommonStockOptionsMember 2021-01-01 2021-09-30 0001133818 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001133818 bpth:CommonStockOptionsMember 2020-01-01 2020-09-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001133818 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001133818 2021-07-01 2021-09-30 0001133818 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001133818 2020-07-01 2020-09-30 0001133818 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001133818 us-gaap:PatentedTechnologyMember 2021-09-30 0001133818 bpth:ManufacturingCostsMember 2021-09-30 0001133818 us-gaap:PatentedTechnologyMember 2020-12-31 0001133818 2021-11-05 0001133818 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001133818 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001133818 bpth:AtMarketOfferingAgreementMember 2021-08-18 2021-08-18 0001133818 bpth:OtherPrepaidExpensesMember bpth:AcutemyeloidleukemiaBp1002InLymphomaAndPrexigebersenMember 2021-09-30 0001133818 us-gaap:CommonStockMember bpth:AtMarketOfferingAgreementMember 2021-01-01 2021-09-30 0001133818 2020-01-01 2020-09-30 0001133818 bpth:AtMarketOfferingAgreementMember 2020-07-13 2020-07-13 0001133818 2020-12-31 0001133818 2021-09-30 0001133818 2021-01-01 2021-09-30 iso4217:USD pure shares iso4217:USD shares

4542000

7160000

BIO-PATH HOLDINGS INC 0001133818 --12-31 2021 Q3 false false

7160164

10-Q true 2021-09-30 false 001-36333 DE 87-0652870 4710 Bellaire Boulevard, Suite 210 Bellaire TX 77401 832 742-1357 Common Stock, par value $0.001 per share BPTH NASDAQ Yes Yes Non-accelerated Filer true false false 7160164

26601000

13755000

2113000

1273000

1519000

928000

30233000

15956000

1076000

1029000

854000

798000

222000

231000

225000

288000

30680000

16475000

417000

100000

657000

975000

88000

94000

1162000

1169000

172000

236000

1334000

1405000

0.001

10000000

0.001

200000000

7160000

4542000

7000

5000

102884000

82286000

-73545000

-67221000

29346000

15070000

30680000

16475000

981000

2000000

3002000

5038000

1088000

970000

3324000

3319000

2069000

2970000

6326000

8357000

-2069000

-2970000

-6326000

-8357000

2000

25000

2000

25000

-2069000

-2968000

-6324000

-8332000

-0.29

-0.80

-0.96

-2.26

7038

3692

6578

3692

-6324000

-8332000

591000

432000

63000 58000

56000

54000

840000

204000

591000

489000

-1000

176000

70000 63000

-7116000

-8368000

47000

-47000

15852000

4157000

20009000

12846000

-8368000

13755000

20426000

26601000

12058000

3692000

4000

77710000

-61703000

16011000

143000

-2968000

3692000

4000

77853000

-64671000

13186000

6960000

7000

101223000

-71476000

29754000

200000

1399000

262000

-2069000

7160000

7000

102884000

-73545000

29346000

3692000

4000

77421000

-56339000

21086000

432000

-8332000

3692000

4000

77853000

-64671000

13186000

4542000

5000

82286000

-67221000

15070000

2189000

2000

15850000

15852000

429000 4157000 4157000

591000

-6324000

7160000

7000

102884000

-73545000

29346000

1. Organization and BusinessThe Company is a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company’s drug delivery and antisense technology, called DNAbilize®, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The Company believes this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo, the DNAbilize® delivered antisense drug substances are systemically distributed throughout the body to allow for reduction or elimination of target proteins in blood diseases and solid tumors. Through testing in numerous animal studies and treatment in over 80 patients, the Company’s DNAbilize® drug candidates have demonstrated an excellent safety profile. DNAbilize® is a registered trademark of the Company. Using DNAbilize® as a platform for drug development and manufacturing, the Company currently has four antisense drug candidates in development to treat at least five different cancer disease indications.The Company was incorporated in May 2000 as a Utah corporation. In February 2008, Bio-Path Subsidiary completed a reverse merger with the Company, which at the time was traded over the counter and had no current operations. The prior name of the Company was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path Subsidiary became the directors and officers of Bio-Path Holdings, Inc. Effective December 31, 2014, the Company changed its state of incorporation from Utah to Delaware through a statutory conversion pursuant to the Utah Revised Business Corporation Act and the Delaware General Corporation Law.The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates. As the Company has not begun its planned principal operations of commercializing a product candidate, the Company’s activities are subject to significant risks and uncertainties, including the potential requirement to secure additional funding, the outcome of the Company’s clinical trials and failing to operationalize the Company’s current drug candidates before another company develops similar products.

2. Significant Accounting PoliciesNet Loss Per Share – Basic net loss per common share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Although there were warrants and stock options outstanding as of September 30, 2021 and 2020, no potential common shares are included in the computation of any diluted per share amount, as they would be antidilutive. Consequently, diluted net loss per share as presented in the condensed consolidated financial statements is equal to basic net loss per share for the three and nine months ended September 30, 2021 and 2020. The calculation of diluted earnings per share for 2021 did not include 485,908 shares and 429,791 shares issuable pursuant to the exercise of outstanding common stock options and warrants, respectively, as of September 30, 2021 as the effect would be antidilutive. The calculation of diluted earnings per share for 2020 did not include 274,008 shares and 858,698 shares issuable pursuant to the exercise of outstanding common stock options and warrants, respectively, as of September 30, 2020 as the effect would be antidilutive.Fair Value - The fair values of cash and cash equivalents, accounts payable and accrued liabilities approximate their carrying values because of the short-term maturities of these instruments.

Net Loss Per Share – Basic net loss per common share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Although there were warrants and stock options outstanding as of September 30, 2021 and 2020, no potential common shares are included in the computation of any diluted per share amount, as they would be antidilutive. Consequently, diluted net loss per share as presented in the condensed consolidated financial statements is equal to basic net loss per share for the three and nine months ended September 30, 2021 and 2020. The calculation of diluted earnings per share for 2021 did not include 485,908 shares and 429,791 shares issuable pursuant to the exercise of outstanding common stock options and warrants, respectively, as of September 30, 2021 as the effect would be antidilutive. The calculation of diluted earnings per share for 2020 did not include 274,008 shares and 858,698 shares issuable pursuant to the exercise of outstanding common stock options and warrants, respectively, as of September 30, 2020 as the effect would be antidilutive.

485908

429791

274008

858698

Fair Value - The fair values of cash and cash equivalents, accounts payable and accrued liabilities approximate their carrying values because of the short-term maturities of these instruments

3. Prepaid Drug ProductAdvance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future clinical development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. The Company recognized certain expenses and incurred installment costs for its contract drug manufacturing and raw material suppliers with prepayments totaling $1.3 million as of December 31, 2020 pursuant to drug supply contracts for the manufacture and delivery of prexigebersen for testing in a Phase 2 clinical trial and BP1002 for testing in a Phase 1 clinical trial. The Company recognized certain expenses and incurred additional installment costs during the first nine months of 2021, with advanced payments remaining to be expensed totaling $2.1 million as of September 30, 2021.

1300000

2100000

4. Other Current AssetsAs of September 30, 2021, other current assets included prepaid expenses of $1.5 million, comprised primarily of prepayments of $1.0 million made for the Company’s clinical trials for BP1002 in lymphoma, prexigebersen in AML and prexigebersen-A in solid tumors as well as prepaid insurance of $0.4 million and prepaid expenses related to preclinical studies of $0.1 million. As of December 31, 2020, other current assets included prepaid expenses of $0.9 million, comprised primarily of prepayments of $0.6 million made for the Company’s clinical trials for BP1002 in lymphoma and prexigebersen-A in solid tumors as well as prepaid insurance of $0.3 million.

1500000

1000000.0

400000

100000

900000

600000

300000

5. Accounts PayableAs of September 30, 2021, current liabilities included accounts payable of $0.4 million, comprised primarily of amounts owed for drug supply manufacturing of $0.3 million and legal and patent fees of $0.1 million. As of December 31, 2020, current liabilities included accounts payable of $0.1 million, comprised primarily of investor relations expenses and legal and patent fees of $0.1 million.

400000

300000

100000

6. Accrued ExpenseAs of September 30, 2021, current liabilities included accrued expenses of $0.7 million, comprised primarily of accrued employee vacation and bonus expenses of $0.3 million, manufacturing and testing services of $0.1 million, professional and consulting fees of $0.1 million, preclinical study expenses of $0.1 million and other accrued expenses of $0.1 million. As of December 31, 2020, current liabilities included accrued expenses of $1.0 million, comprised primarily of expenses related to the Company’s clinical trial for prexigebersen in AML of $0.4 million, accrued employee vacation and bonus expenses of $0.4 million, manufacturing expenses of $0.1 million and other accrued expenses of $0.1 million.

700000

300000 100000

100000

1000000.0

400000 400000 100000

100000

7. Stockholders’ EquityIssuances of Common Stock - On February 16, 2021, the Company entered into a placement agency agreement with Roth Capital Partners, LLC relating to a public offering of 1,710,600 shares of its common stock for gross proceeds of approximately $13.0 million under the Company’s shelf registration statement on Form S-3 (File No. 333-231537) (the “2019 Shelf Registration Statement”), which was declared effective by the SEC on June 5, 2019 (the “2021 Public Offering”). In addition, on February 16, 2021, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to sell an aggregate of 1,650,000 shares of its common stock in the 2021 Public Offering to such investors. The 2021 Public Offering closed on February 18, 2021. The net proceeds from the offerings, after deducting the placement agent’s fees and expenses and the Company’s offering expenses, were approximately $12.2 million.During the nine months ended September 30, 2021, the Company issued an aggregate of 428,907 shares of its common stock pursuant to the exercise of warrants at a weighted average exercise price of approximately $9.71 per share. The net proceeds to the Company from the exercise of the warrants were approximately $4.2 million.At-The-Market Offering Agreement - On July 13, 2020, the Company entered into an At-The-Market Offering Agreement (the “Offering Agreement”) with H. C. Wainwright & Co., LLC (“Wainwright”), as sales agent and/or principal, pursuant to which the Company may offer and sell, from time to time, through or to Wainwright, shares of the Company’s common stock. Sales of shares of common stock under the Offering Agreement were previously made pursuant to the 2019 Shelf Registration Statement and a related prospectus supplement filed with the SEC on July 14, 2020, for an aggregate offering price of up to $7.0 million. From and after August 18, 2021, sales of shares of common stock under the Offering Agreement will be made pursuant to the 2019 Shelf Registration Statement and a related prospectus supplement filed with the SEC on August 18, 2021, for an aggregate offering price of up to $10.0 million. Under the Offering Agreement, Wainwright may sell shares by any method deemed to be an “at the market” offering as defined in Rule 415 under the Securities Act of 1933, as amended. The Company will pay Wainwright a commission of 3% of the aggregate gross proceeds from each sale of shares under the Offering Agreement and has agreed to provide Wainwright with customary indemnification and contribution rights. The Company has also agreed to reimburse Wainwright for certain specified expenses. During the nine months ended September 30, 2021, the Company offered and sold 478,800 shares of its common stock under the Offering Agreement for net proceeds of approximately $3.7 million.Stockholders’ Equity totaled $29.3 million as of September 30, 2021 compared to $15.1 million as of December 31, 2020. There were 7,160,164 shares of common stock issued and outstanding as of September 30, 2021. There were no shares of preferred stock issued and outstanding as of September 30, 2021.

1710600

13000000.0

1650000

12200000

428907 9.71

4200000

7000000.0 10000000.0 0.03

478800

3700000

29300000

15100000

7160164

8. Stock-Based Compensation PlanThe 2017 Plan – On December 21, 2017, the Company’s stockholders approved the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (as amended, the “2017 Plan”), which replaced the First Amended 2007 Stock Incentive Plan, as amended (the “2007 Plan”). The 2007 Plan expired by its terms in January 2018, and no awards were made under the 2007 Plan from the approval of the 2017 Plan on December 21, 2017 until the expiration of the 2007 Plan. The 2017 Plan provides for the grant of Incentive Stock Options, Non-Qualified Stock Options, Restricted Shares, Restricted Share Units, Stock Appreciation Rights, Performance-Based Awards and other stock-based awards, or any combination of the foregoing to the Company’s employees, non-employee directors and consultants. On December 19, 2019, the Company’s stockholders approved an amendment to the 2017 Plan to increase the number of shares reserved for grant and issuance pursuant to the 2017 Plan by 600,000 shares to 660,000 shares. Under the 2017 Plan, the exercise price of awards is determined by the Board of Directors or the compensation committee of the Board of Directors, and for options intended to qualify as qualified Incentive Stock Options, may not be less than the fair market value as determined by the closing stock price at the date of the grant. Each option and award under the 2017 Plan shall vest and expire as determined by the Board of Directors or the compensation committee. Options expire no later than ten years from the date of grant. All grants provide for accelerated vesting if there is a change of control, as defined in the 2017 Plan.Stock-based compensation expense for the three months ended September 30, 2021 and 2020 was $0.3 million and $0.1 million, respectively. Of these amounts, stock-based compensation expense for personnel involved in the Company’s general and administrative activities for the three months ended September 30, 2021 and 2020 was $0.2 million and $0.1 million, respectively. Stock-based compensation expense for personnel involved in the Company’s research and development activities for the three months ended September 30, 2021 and 2020 was $46,000 and $27,000, respectively.Stock-based compensation expense for the nine months ended September 30, 2021 and 2020 was $0.6 million and $0.4 million, respectively. Of these amounts, stock-based compensation expense for personnel involved in the Company’s general and administrative activities for the nine months ended September 30, 2021 and 2020 was $0.5 million and $0.4 million, respectively. Stock-based compensation expense for personnel involved in the Company’s research and development activities for each of the nine months ended September 30, 2021 and 2020 was $0.1 million.The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock options granted, with the following weighted-average assumptions for options granted in the nine months ended September 30, 2021 and 2020, respectively:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 1.15</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">%</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"> 0.50</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 128</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"> 122</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;">Expected term in years</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 6.0</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"> 6.0</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;">Dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;">%</td></tr></table>The following summary represents option activity under the Company’s stock-based compensation plans for the nine months ended September 30, 2021:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;">Weighted-</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;">Exercise</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;">Outstanding at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"> 274</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> 20.57</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 212</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> 7.02</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;">Outstanding at September 30, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 486</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> 14.58</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;">Exercisable at September 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 156</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> 30.83</td></tr></table>As of September 30, 2021, the aggregate intrinsic value of outstanding stock options was $33,000. The aggregate intrinsic value represents the total pretax intrinsic value (the difference between the Company’s closing stock price on September 30, 2021 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on September 30, 2021. This amount changes based on the fair value of the Company’s stock.As of September 30, 2021, unamortized stock-based compensation expense for all outstanding options was $1.6 million, which is expected to be recognized over a weighted average vesting period of 2.7 years.

600000

660000

P10Y

300000

100000

200000

100000

46000

27000

600000

400000

500000

400000

100000

The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock options granted, with the following weighted-average assumptions for options granted in the nine months ended September 30, 2021 and 2020, respectively:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 1.15</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">%</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"> 0.50</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;">Expected volatility</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 128</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"> 122</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;">Expected term in years</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 6.0</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"> 6.0</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;">Dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;">%</td></tr></table>

0.0115

0.0050

1.28

1.22

P6Y

The following summary represents option activity under the Company’s stock-based compensation plans for the nine months ended September 30, 2021:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;">Weighted-</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;">Average</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;">Exercise</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;">Outstanding at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"> 274</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> 20.57</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 212</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> 7.02</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;">Outstanding at September 30, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 486</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> 14.58</td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;">Exercisable at September 30, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 156</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> 30.83</td></tr></table>

274000

20.57

212000

7.02

486000

14.58

156000

30.83

33000

1600000

P2Y8M12D

9. Commitments and ContingenciesDrug Supplier Project Plan –Total commitments for the Company’s drug supplier project plan were $3.0 million as of September 30, 2021, comprised of $1.9 million for the manufacture of prexigebersen, BP1002, and BP1003 drug products, $0.9 million for manufacture of the Company’s Grb2 drug substance, $0.1 million for manufacturing development and $0.1 million for testing services. The Company expects to incur $2.2 million of these commitments over the next 12 months.

3000000.0

1900000

900000

100000

2200000

XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2021	Nov. 05, 2021
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-36333
Entity Registrant Name	BIO-PATH HOLDINGS INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0652870
Entity Address, Address Line One	4710 Bellaire Boulevard, Suite 210
Entity Address, City or Town	Bellaire
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77401
City Area Code	832
Local Phone Number	742-1357
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	BPTH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,160,164
Entity Central Index Key	0001133818
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Amendment Flag	false

XML 11 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash	$ 26,601	$ 13,755
Prepaid drug product	2,113	1,273
Other current assets	1,519	928
Total current assets	30,233	15,956
Fixed assets
Furniture, fixtures & equipment	1,076	1,029
Less accumulated depreciation	(854)	(798)
Furniture, fixtures & equipment, net	222	231
Right of use operating assets	225	288
Total Assets	30,680	16,475
Current liabilities
Accounts payable	417	100
Accrued expenses	657	975
Current portion of lease liabilities	88	94
Total current liabilities	1,162	1,169
Noncurrent lease liabilities	172	236
Total Liabilities	1,334	1,405
Shareholders' equity
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $.001 par value; 200,000 shares authorized; 7,160 and 4,542 shares issued and outstanding, respectively	7	5
Additional paid in capital	102,884	82,286
Accumulated deficit	(73,545)	(67,221)
Total shareholders' equity	29,346	15,070
Total Liabilities & Shareholders' Equity	$ 30,680	$ 16,475

XML 12 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Sep. 30, 2021	Dec. 31, 2020
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000	10,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	200,000	200,000
Common Stock, shares issued	7,160	4,542
Common Stock, shares outstanding	7,160	4,542

XML 13 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses
Research and development	$ 981	$ 2,000	$ 3,002	$ 5,038
General and administrative	1,088	970	3,324	3,319
Total operating expenses	2,069	2,970	6,326	8,357
Net operating loss	(2,069)	(2,970)	(6,326)	(8,357)
Other income
Interest income		2	2	25
Total other income		2	2	25
Net loss	$ (2,069)	$ (2,968)	$ (6,324)	$ (8,332)
Net loss per share, basic and diluted	$ (0.29)	$ (0.80)	$ (0.96)	$ (2.26)
Basic and diluted weighted average number of common shares outstanding	7,038	3,692	6,578	3,692

XML 14 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flow from operating activities
Net loss	$ (6,324)	$ (8,332)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	591	432
Amortization of right of use assets	63	58
Depreciation	56	54
(Increase) decrease in operating assets
Prepaid drug product	(840)	(204)
Other current assets	(591)	(489)
Increase (decrease) in operating liabilities
Accounts payable and accrued expenses	(1)	176
Lease liabilities	(70)	(63)
Net cash used in operating activities	(7,116)	(8,368)
Cash flow from investing activities
Purchases of furniture, fixtures & equipment	(47)
Net cash used in investing activities	(47)
Cash flow from financing activities
Net proceeds from sale of common stock	15,852
Net proceeds from exercise of warrants	4,157
Net cash provided by financing activities	20,009
Net increase (decrease) in cash	12,846	(8,368)
Cash, beginning of period	13,755	20,426
Cash, end of period	$ 26,601	$ 12,058

XML 15 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid in Capital.	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2019	$ 4	$ 77,421	$ (56,339)	$ 21,086
Beginning Balance (in shares) at Dec. 31, 2019	3,692
Stock-based compensation		432		432
Net loss			(8,332)	(8,332)
Ending Balance at Sep. 30, 2020	$ 4	77,853	(64,671)	13,186
Ending Balance (in shares) at Sep. 30, 2020	3,692
Beginning Balance at Jun. 30, 2020	$ 4	77,710	(61,703)	16,011
Beginning Balance (in shares) at Jun. 30, 2020	3,692
Stock-based compensation		143		143
Net loss			(2,968)	(2,968)
Ending Balance at Sep. 30, 2020	$ 4	77,853	(64,671)	13,186
Ending Balance (in shares) at Sep. 30, 2020	3,692
Beginning Balance at Dec. 31, 2020	$ 5	82,286	(67,221)	15,070
Beginning Balance (in shares) at Dec. 31, 2020	4,542
Issuance of common stock, net of fees	$ 2	15,850		15,852
Issuance of common stock, net of fees (in shares)	2,189
Exercise of warrants, net of fees		4,157		4,157
Exercise of warrants, net of fees (in shares)	429
Stock-based compensation		591		591
Net loss			(6,324)	(6,324)
Ending Balance at Sep. 30, 2021	$ 7	102,884	(73,545)	29,346
Ending Balance (in shares) at Sep. 30, 2021	7,160
Beginning Balance at Jun. 30, 2021	$ 7	101,223	(71,476)	29,754
Beginning Balance (in shares) at Jun. 30, 2021	6,960
Issuance of common stock, net of fees		1,399		1,399
Issuance of common stock, net of fees (in shares)	200
Stock-based compensation		262		262
Net loss			(2,069)	(2,069)
Ending Balance at Sep. 30, 2021	$ 7	$ 102,884	$ (73,545)	$ 29,346
Ending Balance (in shares) at Sep. 30, 2021	7,160

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 16 R7.htm IDEA: XBRL DOCUMENT

Organization and Business

9 Months Ended

Sep. 30, 2021

Organization and Business

Organization and Business

1. Organization and Business

XML 17 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Sep. 30, 2021

Significant Accounting Policies

Significant Accounting Policies

2. Significant Accounting Policies

Fair Value - The fair values of cash and cash equivalents, accounts payable and accrued liabilities approximate their carrying values because of the short-term maturities of these instruments.

XML 18 R9.htm IDEA: XBRL DOCUMENT

Prepaid Drug Product

9 Months Ended

Sep. 30, 2021

Prepaid Drug Product

Prepaid Drug Product

3. Prepaid Drug Product

XML 19 R10.htm IDEA: XBRL DOCUMENT

Other Current Assets

9 Months Ended

Sep. 30, 2021

Other Current Assets

Other Current Assets

4. Other Current Assets

XML 20 R11.htm IDEA: XBRL DOCUMENT

Accounts Payable

9 Months Ended

Sep. 30, 2021

Accounts Payable

Accounts Payable

5. Accounts Payable

XML 21 R12.htm IDEA: XBRL DOCUMENT

Accrued Expense

9 Months Ended

Sep. 30, 2021

Accrued Expense

Accrued Expense

6. Accrued Expense

XML 22 R13.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2021

Stockholders' Equity

Stockholders' Equity

7. Stockholders’ Equity

During the nine months ended September 30, 2021, the Company offered and sold 478,800 shares of its common stock under the Offering Agreement for net proceeds of approximately $3.7 million.

XML 23 R14.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation Plan

9 Months Ended

Sep. 30, 2021

Stock-Based Compensation Plan

Stock-Based Compensation Plan

8. Stock-Based Compensation Plan


	2021		2020
Risk-free interest rate	1.15	%	0.50	%
Expected volatility	128	%	122	%
Expected term in years	6.0		6.0
Dividend yield	—	%	—	%

The following summary represents option activity under the Company’s stock-based compensation plans for the nine months ended September 30, 2021:


		Weighted-
		Average
		Exercise
	Options	Price
	(in thousands)
Outstanding at December 31, 2020	274	$	20.57
Granted	212		7.02
Outstanding at September 30, 2021	486		14.58
Exercisable at September 30, 2021	156	$	30.83

XML 24 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2021

Commitments and Contingencies

Commitments and Contingencies

9. Commitments and Contingencies

XML 25 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2021
Significant Accounting Policies
Net Loss Per Share	Net Loss Per Share – Basic net loss per common share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Although there were warrants and stock options outstanding as of September 30, 2021 and 2020, no potential common shares are included in the computation of any diluted per share amount, as they would be antidilutive. Consequently, diluted net loss per share as presented in the condensed consolidated financial statements is equal to basic net loss per share for the three and nine months ended September 30, 2021 and 2020. The calculation of diluted earnings per share for 2021 did not include 485,908 shares and 429,791 shares issuable pursuant to the exercise of outstanding common stock options and warrants, respectively, as of September 30, 2021 as the effect would be antidilutive. The calculation of diluted earnings per share for 2020 did not include 274,008 shares and 858,698 shares issuable pursuant to the exercise of outstanding common stock options and warrants, respectively, as of September 30, 2020 as the effect would be antidilutive.
Fair Value	Fair Value - The fair values of cash and cash equivalents, accounts payable and accrued liabilities approximate their carrying values because of the short-term maturities of these instruments

XML 26 R17.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation Plan (Tables)

9 Months Ended

Sep. 30, 2021

Stock-Based Compensation Plan

Schedule of share-based payment award, stock options, valuation assumptions


	2021		2020
Risk-free interest rate	1.15	%	0.50	%
Expected volatility	128	%	122	%
Expected term in years	6.0		6.0
Dividend yield	—	%	—	%

Schedule of option activity under stock-based compensation plans

The following summary represents option activity under the Company’s stock-based compensation plans for the nine months ended September 30, 2021:


		Weighted-
		Average
		Exercise
	Options	Price
	(in thousands)
Outstanding at December 31, 2020	274	$	20.57
Granted	212		7.02
Outstanding at September 30, 2021	486		14.58
Exercisable at September 30, 2021	156	$	30.83

XML 27 R18.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - shares	9 Months Ended
Significant Accounting Policies (Details) - shares	Sep. 30, 2021	Sep. 30, 2020
Common Stock Options [Member]
Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	485,908	274,008
Warrant [Member]
Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	429,791	858,698

XML 28 R19.htm IDEA: XBRL DOCUMENT

Prepaid Drug Product (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Prepaid Drug Product
Prepaid drug product for testing		$ 1.3
Advanced payments remaining to be expensed	$ 2.1

XML 29 R20.htm IDEA: XBRL DOCUMENT

Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Other current assets	$ 1,519	$ 928
Prepaid Expenses [Member]
Other current assets	1,500	900
Prepaid Expenses [Member] \| BP1002 in lymphoma, prexigebersen in AML and prexigebersen-A [Member]
Other current assets	1,000	600
Other Prepaid Expenses [Member] \| BP1002 in lymphoma, prexigebersen in AML and prexigebersen-A [Member]
Prepaid insurance	400	$ 300
Prepaid expenses related to preclinical studies	$ 100

XML 30 R21.htm IDEA: XBRL DOCUMENT

Accounts Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accounts Payable [Line Items]
Accounts payable, current	$ 417	$ 100
Manufacturing Costs [Member]
Accounts Payable [Line Items]
Accounts payable, current	300
Legal and Patent [Member]
Accounts Payable [Line Items]
Accounts payable, current	$ 100	$ 100

XML 31 R22.htm IDEA: XBRL DOCUMENT

Accrued Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accrued Expense
Accrued expense	$ 657	$ 975
Accrued clinical trial expenses		400
Accrued vacation and bonus expenses	300	400
Manufacturing and testing services	100
Manufacturing expenses		100
Professional and consulting fees	100
Accrued clinical and preclinical expenses	100
Other accrued expenses	$ 100	$ 100

XML 32 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended	9 Months Ended
	Aug. 18, 2021	Feb. 18, 2021	Feb. 16, 2021	Jul. 13, 2020	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Shareholders Equity [Line Items]
Net proceeds from sale of common stock		$ 12,200				$ 15,852
Issuance of common stock, net of fees					$ 1,399	$ 15,852
Stock issued during period shares warrants exercised						428,907
Proceeds from warrant exercises						$ 4,200
Weighted average exercise price						$ 9.71
Stockholders' Equity total amount					$ 29,346	$ 29,346	$ 29,754	$ 15,070	$ 13,186	$ 16,011	$ 21,086
Common Stock, shares issued					7,160,000	7,160,000		4,542,000
Common Stock, shares outstanding					7,160,000	7,160,000		4,542,000
Preferred Stock, shares issued					0	0		0
Preferred Stock, shares outstanding					0	0		0
Common Stock
Shareholders Equity [Line Items]
Shares issued (in shares)					200,000	2,189,000
Issuance of common stock, net of fees						$ 2
Stockholders' Equity total amount					$ 7	7	$ 7	$ 5	$ 4	$ 4	$ 4
IPO [Member]
Shareholders Equity [Line Items]
Shares issued (in shares)			1,710,600
Net proceeds from sale of common stock			$ 13,000
2021 Public Offering [Member]
Shareholders Equity [Line Items]
Shares issued (in shares)			1,650,000
At-The-Market Offering Agreement [Member]
Shareholders Equity [Line Items]
Maximum aggregate offering price	$ 10,000			$ 7,000
Commission on aggregate gross proceeds (as a percent)				3.00%
Stockholders' Equity total amount					$ 29,300	$ 29,300		$ 15,100
At-The-Market Offering Agreement [Member] \| Common Stock
Shareholders Equity [Line Items]
Shares issued (in shares)						478,800
Net proceeds						$ 3,700
Common Stock, shares issued					7,160,164	7,160,164
Common Stock, shares outstanding					7,160,164	7,160,164
At-The-Market Offering Agreement [Member] \| Preferred Stock
Shareholders Equity [Line Items]
Preferred Stock, shares issued					0	0
Preferred Stock, shares outstanding					0	0

XML 33 R24.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation Plan - Weighted-Average Assumptions (Details)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Stock-Based Compensation Plan
Risk-free interest rate	1.15%	0.50%
Expected volatility	128.00%	122.00%
Expected term in years	6 years	6 years
Dividend yield	0.00%	0.00%

XML 34 R25.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation Plan - Option Activity Under Plan (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2021 $ / shares shares
Stock-Based Compensation Plan
Outstanding \| shares	274
Granted \| shares	212
Outstanding \| shares	486
Exercisable \| shares	156
Weighted-Average Exercise Price, Outstanding \| $ / shares	$ 20.57
Weighted-Average Exercise Price, Granted \| $ / shares	7.02
Weighted-Average Exercise Price, Outstanding \| $ / shares	14.58
Weighted-Average Exercise Price, Exercisable \| $ / shares	$ 30.83

XML 35 R26.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation Plan - Narrative (Details) - USD ($)		3 Months Ended		9 Months Ended
	Dec. 19, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stock Based Compensation Plans [Line Items]
Unamortized stock-based compensation expense for outstanding options		$ 1,600,000		$ 1,600,000
Stock-based compensation expense		300,000	$ 100,000	600,000	$ 400,000
Aggregate intrinsic value of outstanding stock options		33,000		$ 33,000
Weighted average vesting period				2 years 8 months 12 days
Stock Incentive Plan 2017 [Member]
Stock Based Compensation Plans [Line Items]
Increase in number of shares reserved for grant	600,000
Number of shares reserved for grant and issuance	660,000
Expiration period (in years)				10 years
Research and Development Expense [Member]
Stock Based Compensation Plans [Line Items]
Stock-based compensation expense		46,000	27,000	$ 100,000	100,000
General and Administrative Expense [Member]
Stock Based Compensation Plans [Line Items]
Stock-based compensation expense		$ 200,000	$ 100,000	$ 500,000	$ 400,000

XML 36 R27.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) $ in Millions	Sep. 30, 2021 USD ($)
Product Liability Contingency [Line Items]
Other Commitment, Due in Next Twelve Months	$ 2.2
Drug Supplier Project Plan [Member]
Product Liability Contingency [Line Items]
Other Commitment	3.0
Manufacture of Prexigebersen [Member]
Product Liability Contingency [Line Items]
Other Commitment	1.9
Manufacture of Drug Substance [Member]
Product Liability Contingency [Line Items]
Other Commitment	0.9
Manufacturing Development [Member]
Product Liability Contingency [Line Items]
Other Commitment	0.1
Testing Services [Member]
Product Liability Contingency [Line Items]
Other Commitment	$ 0.1

EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 78 205 1 false 22 0 false 4 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 10101 - Disclosure - Organization and Business Sheet http://www.biopathholdings.com/role/DisclosureOrganizationAndBusiness Organization and Business Notes 7 false false R8.htm 10201 - Disclosure - Significant Accounting Policies Sheet http://www.biopathholdings.com/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Prepaid Drug Product Sheet http://www.biopathholdings.com/role/DisclosurePrepaidDrugProduct Prepaid Drug Product Notes 9 false false R10.htm 10401 - Disclosure - Other Current Assets Sheet http://www.biopathholdings.com/role/DisclosureOtherCurrentAssets Other Current Assets Notes 10 false false R11.htm 10501 - Disclosure - Accounts Payable Sheet http://www.biopathholdings.com/role/DisclosureAccountsPayable Accounts Payable Notes 11 false false R12.htm 10601 - Disclosure - Accrued Expense Sheet http://www.biopathholdings.com/role/DisclosureAccruedExpense Accrued Expense Notes 12 false false R13.htm 10701 - Disclosure - Stockholders' Equity Sheet http://www.biopathholdings.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 10801 - Disclosure - Stock-Based Compensation Plan Sheet http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlan Stock-Based Compensation Plan Notes 14 false false R15.htm 10901 - Disclosure - Commitments and Contingencies Sheet http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 20202 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.biopathholdings.com/role/DisclosureSignificantAccountingPolicies 16 false false R17.htm 30803 - Disclosure - Stock-Based Compensation Plan (Tables) Sheet http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanTables Stock-Based Compensation Plan (Tables) Tables http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlan 17 false false R18.htm 40201 - Disclosure - Significant Accounting Policies (Details) Sheet http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesPolicies 18 false false R19.htm 40301 - Disclosure - Prepaid Drug Product (Details) Sheet http://www.biopathholdings.com/role/DisclosurePrepaidDrugProductDetails Prepaid Drug Product (Details) Details http://www.biopathholdings.com/role/DisclosurePrepaidDrugProduct 19 false false R20.htm 40401 - Disclosure - Other Current Assets (Details) Sheet http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails Other Current Assets (Details) Details http://www.biopathholdings.com/role/DisclosureOtherCurrentAssets 20 false false R21.htm 40501 - Disclosure - Accounts Payable (Details) Sheet http://www.biopathholdings.com/role/DisclosureAccountsPayableDetails Accounts Payable (Details) Details http://www.biopathholdings.com/role/DisclosureAccountsPayable 21 false false R22.htm 40601 - Disclosure - Accrued Expense (Details) Sheet http://www.biopathholdings.com/role/DisclosureAccruedExpenseDetails Accrued Expense (Details) Details http://www.biopathholdings.com/role/DisclosureAccruedExpense 22 false false R23.htm 40701 - Disclosure - Stockholders' Equity (Details) Sheet http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) Details http://www.biopathholdings.com/role/DisclosureStockholdersEquity 23 false false R24.htm 40801 - Disclosure - Stock-Based Compensation Plan - Weighted-Average Assumptions (Details) Sheet http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanWeightedAverageAssumptionsDetails Stock-Based Compensation Plan - Weighted-Average Assumptions (Details) Details 24 false false R25.htm 40802 - Disclosure - Stock-Based Compensation Plan - Option Activity Under Plan (Details) Sheet http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanOptionActivityUnderPlanDetails Stock-Based Compensation Plan - Option Activity Under Plan (Details) Details 25 false false R26.htm 40803 - Disclosure - Stock-Based Compensation Plan - Narrative (Details) Sheet http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails Stock-Based Compensation Plan - Narrative (Details) Details 26 false false R27.htm 40901 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingencies 27 false false All Reports Book All Reports bpth-20210930x10q.htm bpth-20210930.xsd bpth-20210930_cal.xml bpth-20210930_def.xml bpth-20210930_lab.xml bpth-20210930_pre.xml bpth-20210930xex31d1.htm bpth-20210930xex32.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 43 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bpth-20210930x10q.htm": { "axisCustom": 0, "axisStandard": 7, "contextCount": 78, "dts": { "calculationLink": { "local": [ "bpth-20210930_cal.xml" ] }, "definitionLink": { "local": [ "bpth-20210930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "bpth-20210930x10q.htm" ] }, "labelLink": { "local": [ "bpth-20210930_lab.xml" ] }, "presentationLink": { "local": [ "bpth-20210930_pre.xml" ] }, "schema": { "local": [ "bpth-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 215, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 6, "http://xbrl.sec.gov/dei/2020-01-31": 7, "total": 13 }, "keyCustom": 19, "keyStandard": 186, "memberCustom": 13, "memberStandard": 9, "nsprefix": "bpth", "nsuri": "http://www.biopathholdings.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Other Current Assets", "role": "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssets", "shortName": "Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "bpth:AccountsPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Accounts Payable", "role": "http://www.biopathholdings.com/role/DisclosureAccountsPayable", "shortName": "Accounts Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "bpth:AccountsPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Accrued Expense", "role": "http://www.biopathholdings.com/role/DisclosureAccruedExpense", "shortName": "Accrued Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Stockholders' Equity", "role": "http://www.biopathholdings.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Stock-Based Compensation Plan", "role": "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlan", "shortName": "Stock-Based Compensation Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Commitments and Contingencies", "role": "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Stock-Based Compensation Plan (Tables)", "role": "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanTables", "shortName": "Stock-Based Compensation Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_bpth_CommonStockOptionsMember_cuAqKlloe02K-XVRatLwMg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_vIv_JbutrUGB-SxeLrLAJQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Significant Accounting Policies (Details)", "role": "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_bpth_CommonStockOptionsMember_cuAqKlloe02K-XVRatLwMg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_vIv_JbutrUGB-SxeLrLAJQ", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "p", "bpth:ResearchAndDevelopmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_12_31_2020_9tPivupJ-UKOs1KV-1Ecww", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Prepaid Drug Product (Details)", "role": "http://www.biopathholdings.com/role/DisclosurePrepaidDrugProductDetails", "shortName": "Prepaid Drug Product (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "bpth:ResearchAndDevelopmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_12_31_2020_9tPivupJ-UKOs1KV-1Ecww", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NCNp6sd_00GjqQq9HTU0hg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NCNp6sd_00GjqQq9HTU0hg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NCNp6sd_00GjqQq9HTU0hg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Other Current Assets (Details)", "role": "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails", "shortName": "Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_us-gaap_BalanceSheetLocationAxis_bpth_PrepaidExpensesMember_B8iuyZoOikOgEGXv6OO6XA", "decimals": "-5", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NCNp6sd_00GjqQq9HTU0hg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Accounts Payable (Details)", "role": "http://www.biopathholdings.com/role/DisclosureAccountsPayableDetails", "shortName": "Accounts Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "bpth:AccountsPayableDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_us-gaap_IncomeStatementLocationAxis_bpth_ManufacturingCostsMember_mLZpDxbLZEC9-PuUZe1Wbg", "decimals": "-5", "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NCNp6sd_00GjqQq9HTU0hg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Accrued Expense (Details)", "role": "http://www.biopathholdings.com/role/DisclosureAccruedExpenseDetails", "shortName": "Accrued Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_12_31_2020_9tPivupJ-UKOs1KV-1Ecww", "decimals": "-5", "lang": null, "name": "bpth:AccruedClinicalTrialExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_2_18_2021_To_2_18_2021_l-LJ6ulSxUGh2HdQ3f1dRQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Stockholders' Equity (Details)", "role": "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_2_18_2021_To_2_18_2021_l-LJ6ulSxUGh2HdQ3f1dRQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_yyTeqVppjUKS42tDcj9yGA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Stock-Based Compensation Plan - Weighted-Average Assumptions (Details)", "role": "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanWeightedAverageAssumptionsDetails", "shortName": "Stock-Based Compensation Plan - Weighted-Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_yyTeqVppjUKS42tDcj9yGA", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_12_31_2020_9tPivupJ-UKOs1KV-1Ecww", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_vIv_JbutrUGB-SxeLrLAJQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Stock-Based Compensation Plan - Option Activity Under Plan (Details)", "role": "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanOptionActivityUnderPlanDetails", "shortName": "Stock-Based Compensation Plan - Option Activity Under Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_12_31_2020_9tPivupJ-UKOs1KV-1Ecww", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_vIv_JbutrUGB-SxeLrLAJQ", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NCNp6sd_00GjqQq9HTU0hg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Stock-Based Compensation Plan - Narrative (Details)", "role": "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails", "shortName": "Stock-Based Compensation Plan - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_oxjISpnESEqdeT_UEJFKgw", "decimals": "-5", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NCNp6sd_00GjqQq9HTU0hg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherCommitmentDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NCNp6sd_00GjqQq9HTU0hg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherCommitmentDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NCNp6sd_00GjqQq9HTU0hg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_b9M6mUpTy0-p-65EvPQ_lQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_9_30_2021_NCNp6sd_00GjqQq9HTU0hg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_b9M6mUpTy0-p-65EvPQ_lQ", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_oxjISpnESEqdeT_UEJFKgw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_oxjISpnESEqdeT_UEJFKgw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_n51O2ztkQE6Whxs7LaFVvg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "role": "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YPeoh41tlkaU1hpVzlhlJQ", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_CTVft-qlAEeSqjAYf4eXGQ", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Organization and Business", "role": "http://www.biopathholdings.com/role/DisclosureOrganizationAndBusiness", "shortName": "Organization and Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Significant Accounting Policies", "role": "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "bpth:ResearchAndDevelopmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Prepaid Drug Product", "role": "http://www.biopathholdings.com/role/DisclosurePrepaidDrugProduct", "shortName": "Prepaid Drug Product", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpth-20210930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_uj5tVOoKmkGziHRUcAeClA", "decimals": null, "first": true, "lang": "en-US", "name": "bpth:ResearchAndDevelopmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 22, "tag": { "bpth_AccountsPayableDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable" } } }, "localname": "AccountsPayableDisclosureAbstract", "nsuri": "http://www.biopathholdings.com/20210930", "xbrltype": "stringItemType" }, "bpth_AccountsPayableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable at the end of the reporting period.", "label": "Accounts Payable Disclosure [Text Block]", "verboseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableDisclosureTextBlock", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccountsPayable" ], "xbrltype": "textBlockItemType" }, "bpth_AccountsPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable [Line Items]", "verboseLabel": "Accounts Payable [Line Items]" } } }, "localname": "AccountsPayableLineItems", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccountsPayableDetails" ], "xbrltype": "stringItemType" }, "bpth_AccountsPayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable [Table]" } } }, "localname": "AccountsPayableTable", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccountsPayableDetails" ], "xbrltype": "stringItemType" }, "bpth_AccruedClinicalAndPreclinicalExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for clinical and preclinical expenses.", "label": "Accrued Clinical And Preclinical Expenses", "terseLabel": "Accrued clinical and preclinical expenses" } } }, "localname": "AccruedClinicalAndPreclinicalExpenses", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccruedExpenseDetails" ], "xbrltype": "monetaryItemType" }, "bpth_AccruedClinicalTrialExpensesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the Company's clinical trial (due within one year or within the normal operating cycle if longer).", "label": "Accrued Clinical Trial Expenses, Current", "terseLabel": "Accrued clinical trial expenses" } } }, "localname": "AccruedClinicalTrialExpensesCurrent", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccruedExpenseDetails" ], "xbrltype": "monetaryItemType" }, "bpth_AccruedManufacturingAndTestingExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for manufacturing and testing services.", "label": "Accrued Manufacturing And Testing Expenses", "terseLabel": "Manufacturing and testing services" } } }, "localname": "AccruedManufacturingAndTestingExpenses", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccruedExpenseDetails" ], "xbrltype": "monetaryItemType" }, "bpth_AccruedManufacturingExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued manufacturing expense.", "label": "Accrued Manufacturing Expense", "terseLabel": "Manufacturing expenses" } } }, "localname": "AccruedManufacturingExpense", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccruedExpenseDetails" ], "xbrltype": "monetaryItemType" }, "bpth_AccruedVacationAndBonus": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for employee vacation and bonus expenses .", "label": "Accrued Vacation And Bonus", "terseLabel": "Accrued vacation and bonus expenses" } } }, "localname": "AccruedVacationAndBonus", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccruedExpenseDetails" ], "xbrltype": "monetaryItemType" }, "bpth_AcutemyeloidleukemiaBp1002InLymphomaAndPrexigebersenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to BP1002 in lymphoma and prexigebersen-A.", "label": "Acutemyeloidleukemia Bp1002 In Lymphoma And Prexigebersen [Member]", "terseLabel": "BP1002 in lymphoma, prexigebersen in AML and prexigebersen-A [Member]" } } }, "localname": "AcutemyeloidleukemiaBp1002InLymphomaAndPrexigebersenMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "bpth_AtMarketOfferingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-The-Market Offering Agreement [Member].", "label": "At Market Offering Agreement [Member]", "terseLabel": "At-The-Market Offering Agreement [Member]" } } }, "localname": "AtMarketOfferingAgreementMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "bpth_CommissionPercentageOnAggregateGrossProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the commission on aggregate gross proceeds.", "label": "Commission Percentage On Aggregate Gross Proceeds", "terseLabel": "Commission on aggregate gross proceeds (as a percent)" } } }, "localname": "CommissionPercentageOnAggregateGrossProceeds", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "bpth_CommonStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to common stock options.", "label": "Common Stock Options [Member]", "terseLabel": "Common Stock Options [Member]" } } }, "localname": "CommonStockOptionsMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bpth_DisclosureStockholdersEquityAdditionalInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure - Stockholders' Equity - Additional Information [Abstract]", "label": "Stockholders' Equity." } } }, "localname": "DisclosureStockholdersEquityAdditionalInformationAbstract", "nsuri": "http://www.biopathholdings.com/20210930", "xbrltype": "stringItemType" }, "bpth_DrugSupplierProjectPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Drug Supplier Project Plan [Member].", "label": "Drug Supplier Project Plan [Member]", "terseLabel": "Drug Supplier Project Plan [Member]" } } }, "localname": "DrugSupplierProjectPlanMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "bpth_ExpectedAdvancedPaymentToBeExpensed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of advanced payments remaining to be expensed.", "label": "Expected Advanced Payment to be Expensed", "terseLabel": "Advanced payments remaining to be expensed" } } }, "localname": "ExpectedAdvancedPaymentToBeExpensed", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosurePrepaidDrugProductDetails" ], "xbrltype": "monetaryItemType" }, "bpth_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "negatedLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bpth_ManufactureOfDrugSubstanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacture of Drug Substance [Member].", "label": "Manufacture Of Drug Substance [Member]", "terseLabel": "Manufacture of Drug Substance [Member]" } } }, "localname": "ManufactureOfDrugSubstanceMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "bpth_ManufacturerOfPrexigebersenAndBp1002DrugProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to manufacturer of prexigebersen and BP1002 drug products.", "label": "Manufacturer Of Prexigebersen And Bp1002 Drug Products [Member]", "terseLabel": "Manufacture of Prexigebersen [Member]" } } }, "localname": "ManufacturerOfPrexigebersenAndBp1002DrugProductsMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "bpth_ManufacturingCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing Costs [Member].", "label": "Manufacturing Costs [Member]", "terseLabel": "Manufacturing Costs [Member]" } } }, "localname": "ManufacturingCostsMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccountsPayableDetails" ], "xbrltype": "domainItemType" }, "bpth_ManufacturingDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing Development [Member].", "label": "Manufacturing Development [Member]", "terseLabel": "Manufacturing Development [Member]" } } }, "localname": "ManufacturingDevelopmentMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "bpth_NetProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity, after deducting commission and offering expenses.", "label": "Net Proceeds From Issuance Of Common Stock", "terseLabel": "Net proceeds" } } }, "localname": "NetProceedsFromIssuanceOfCommonStock", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "bpth_OperatingLeaseRightOfUseAssetsAmortization": { "auth_ref": [], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease right-of-use assets amortization.", "label": "Operating Lease Right of Use Assets Amortization", "verboseLabel": "Amortization of right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetsAmortization", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bpth_OtherPrepaidExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Prepaid Expenses [Member].", "label": "Other Prepaid Expenses [Member]", "terseLabel": "Other Prepaid Expenses [Member]" } } }, "localname": "OtherPrepaidExpensesMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "bpth_PrepaidDrugProductForTestingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Drug Product" } } }, "localname": "PrepaidDrugProductForTestingAbstract", "nsuri": "http://www.biopathholdings.com/20210930", "xbrltype": "stringItemType" }, "bpth_PrepaidExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Expenses [Member].", "label": "Prepaid Expenses [Member]", "terseLabel": "Prepaid Expenses [Member]" } } }, "localname": "PrepaidExpensesMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "bpth_PrepaidExpensesRelatedToPreclinicalStudies": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prepaid expenses related to preclinical studies", "label": "Prepaid Expenses Related to Preclinical Studies", "terseLabel": "Prepaid expenses related to preclinical studies" } } }, "localname": "PrepaidExpensesRelatedToPreclinicalStudies", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "bpth_ResearchAndDevelopmentDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development Disclosure [Text Block]", "label": "Research and Development Disclosure [Text Block]", "terseLabel": "Prepaid Drug Product" } } }, "localname": "ResearchAndDevelopmentDisclosureTextBlock", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosurePrepaidDrugProduct" ], "xbrltype": "textBlockItemType" }, "bpth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndUnvestedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding and unvested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Unvested Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted average vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndUnvestedWeightedAverageRemainingContractualTerm", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "durationItemType" }, "bpth_ShareholdersEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholders Equity [Line Items]", "label": "Shareholders Equity [Line Items]", "terseLabel": "Shareholders Equity [Line Items]" } } }, "localname": "ShareholdersEquityLineItems", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "bpth_ShareholdersEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholders Equity [Table]", "label": "Shareholders Equity [Table]" } } }, "localname": "ShareholdersEquityTable", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "bpth_SharesProceedsAuthorized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the maximum gross sales proceeds.", "label": "Shares Proceeds Authorized", "terseLabel": "Maximum aggregate offering price" } } }, "localname": "SharesProceedsAuthorized", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "bpth_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "bpth_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "bpth_StockBasedCompensationPlansLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Based Compensation Plans [Line Items]" } } }, "localname": "StockBasedCompensationPlansLineItems", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "stringItemType" }, "bpth_StockBasedCompensationPlansTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Based Compensation Plans [Table]" } } }, "localname": "StockBasedCompensationPlansTable", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "stringItemType" }, "bpth_StockIncentivePlan2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2017 Stock Incentive Plan.", "label": "Stock Incentive Plan2017 [Member]", "terseLabel": "Stock Incentive Plan 2017 [Member]" } } }, "localname": "StockIncentivePlan2017Member", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "bpth_StockIssueDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period warrants exercised.", "label": "Stock Issue During Period Shares Warrants Exercised", "verboseLabel": "Exercise of warrants, net of fees (in shares)" } } }, "localname": "StockIssueDuringPeriodSharesWarrantsExercised", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "bpth_StockIssueDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of warrants exercised during the period.", "label": "Stock Issue During Period Value Warrants Exercised", "verboseLabel": "Exercise of warrants, net of fees" } } }, "localname": "StockIssueDuringPeriodValueWarrantsExercised", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "bpth_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period Shares Warrants Exercised", "terseLabel": "Stock issued during period shares warrants exercised" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "bpth_TestingServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Testing Services [Member].", "label": "Testing Services [Member]", "terseLabel": "Testing Services [Member]" } } }, "localname": "TestingServicesMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "bpth_TwoThousandTwentyOnePublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty-One Public Offering [Member].", "label": "Two Thousand Twenty One Public Offering [Member]", "terseLabel": "2021 Public Offering [Member]" } } }, "localname": "TwoThousandTwentyOnePublicOfferingMember", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "bpth_WeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to weighted average exercise price of common stock issued pursuant to exercise of warrants.", "label": "Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price" } } }, "localname": "WeightedAverageExercisePrice", "nsuri": "http://www.biopathholdings.com/20210930", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expense" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccruedExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "verboseLabel": "Accounts payable, current" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccountsPayableDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expense", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccruedExpenseDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expense" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r8", "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional and consulting fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccruedExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r20", "r83" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r13", "r122" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid In Capital", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r49", "r50", "r51", "r119", "r120", "r121" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid in Capital." } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "verboseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r100", "r115", "r124" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r47", "r67", "r69", "r73", "r76", "r132", "r134", "r139", "r150", "r154" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r28", "r47", "r76", "r132", "r134", "r139" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Fixed assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r137", "r138" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r18", "r165", "r166" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r38", "r43", "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r38", "r140" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Period Increase (Decrease)", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r86", "r87", "r88", "r96" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r49", "r50" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r12", "r97" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r12" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $.001 par value; 200,000 shares authorized; 7,160 and 4,542 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r41", "r81" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "verboseLabel": "Stock-Based Compensation Plan" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation Plan" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r45", "r63", "r64" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r116" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "verboseLabel": "Unamortized stock-based compensation expense for outstanding options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r49", "r50", "r51", "r53", "r58", "r60", "r65", "r77", "r97", "r98", "r119", "r120", "r121", "r129", "r130", "r141", "r142", "r143", "r144", "r145", "r146", "r160", "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesDetails", "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "verboseLabel": "Fair Value" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r33" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccountsPayableDetails", "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccountsPayableDetails", "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r40" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "(Increase) decrease in operating assets" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Liabilities [Abstract]", "terseLabel": "Increase (decrease) in operating liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r40" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r40" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid drug product" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r34", "r66" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r23", "r47", "r70", "r76", "r133", "r134", "r135", "r139" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r17", "r47", "r76", "r139", "r151", "r156" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities & Shareholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities & Shareholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r25", "r47", "r76", "r133", "r134", "r135", "r139" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r38" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flow from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r38" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flow from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r38", "r39", "r42" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flow from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r29", "r30", "r31", "r42", "r47", "r52", "r54", "r55", "r56", "r57", "r59", "r60", "r61", "r67", "r68", "r71", "r72", "r74", "r76", "r139", "r153", "r159" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r35" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r67", "r68", "r71", "r72", "r74" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Net operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r148" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Current portion of lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r148" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Noncurrent lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r147" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right of use operating assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOrganizationAndBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r152", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccruedExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Other Commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentDueInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Other Commitment, Due in Next Twelve Months", "terseLabel": "Other Commitment, Due in Next Twelve Months" } } }, "localname": "OtherCommitmentDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "verboseLabel": "Other Current Assets" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r2", "r5", "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "verboseLabel": "Prepaid drug product for testing" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosurePrepaidDrugProductDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentedTechnologyMember": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patented technology to exploit the technology for a period of time specified by law.", "label": "Patented Technology [Member]", "terseLabel": "Legal and Patent [Member]" } } }, "localname": "PatentedTechnologyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureAccountsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r36" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of furniture, fixtures & equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r101", "r117" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r11" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r2", "r5", "r79", "r80" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "verboseLabel": "Prepaid drug product" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r3", "r5", "r78", "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r37" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r37", "r118" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Net proceeds from exercise of warrants" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from warrant exercises" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductLiabilityContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Liability Contingency [Line Items]", "terseLabel": "Product Liability Contingency [Line Items]" } } }, "localname": "ProductLiabilityContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyTable": { "auth_ref": [ "r89", "r90", "r91", "r92", "r93", "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product.", "label": "Product Liability Contingency [Table]" } } }, "localname": "ProductLiabilityContingencyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r19", "r82" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Furniture, fixtures & equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r84", "r157" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Furniture, fixtures & equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r127", "r128" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r127", "r128" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r126", "r167" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r14", "r98", "r122", "r155", "r163", "r164" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r49", "r50", "r51", "r53", "r58", "r60", "r77", "r119", "r120", "r121", "r129", "r130", "r160", "r162" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r103", "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of option activity under stock-based compensation plans" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Schedule of share-based payment award, stock options, valuation assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r40" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase in number of shares reserved for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Number of shares reserved for grant and issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanOptionActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Weighted-Average Exercise Price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanOptionActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanOptionActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r105", "r117" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding", "periodStartLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanOptionActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Outstanding", "periodStartLabel": "Weighted-Average Exercise Price, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanOptionActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "verboseLabel": "Aggregate intrinsic value of outstanding stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted-Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanOptionActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r111", "r123" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockBasedCompensationPlanWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r26", "r49", "r50", "r51", "r53", "r58", "r60", "r65", "r77", "r97", "r98", "r119", "r120", "r121", "r129", "r130", "r141", "r142", "r143", "r144", "r145", "r146", "r160", "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesDetails", "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r49", "r50", "r51", "r65", "r149" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureOtherCurrentAssetsDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r12", "r97", "r98" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares issued (in shares)", "verboseLabel": "Issuance of common stock, net of fees (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r12", "r97", "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common stock, net of fees" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r12", "r15", "r16", "r47", "r75", "r76", "r139" ], "calculation": { "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total shareholders' equity", "verboseLabel": "Stockholders' Equity total amount" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r46", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/DisclosureSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.biopathholdings.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r168": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r169": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r171": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r172": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r173": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" } }, "version": "2.1" } ZIP 44 0001558370-21-015489-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-21-015489-xbrl.zip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�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
% M 0!B<'1H+3(P,C$P.3,P>&5X,S(N:'1M4$L%!@ ( @ & ( .J* 0 ! $! end